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Abstract
This dissertation focuses on developing Bayesian survival analysis methodology
for optimizing decision making and treatment methods in a variety of biomedical
applications.
First, we develop a flexible Bayesian nonparametric regression model based on a
dependent Dirichlet process and Gaussian process, DDP-GP, for optimizing precision
dosing of intravenous busulfan in allogenic stem cell transplantation. Our analyses of a
dataset of 151 patients identified optimal therapeutic dosage intervals that maximizes
patient survival outcomes and varies substantively with age and complete remission
status. Extensive simulations to evaluate the DDP-GP model in similar settings
showed that its performance compares favorably to alternative methods. We provide
an R package, DDPGPSurv, that implements the DDP-GP model for a wide range of
survival regression analyses.
The second main contribution of this dissertation is the development of person-
alized dynamic treatment regimes (DTR) in continuous time. Traditional statistical
methods for DTRs usually focus on estimating the optimal treatment or dosage at
each given medical intervention, but overlook the important question of “when this
intervention should happen.” We fill this gap by building a generative model for a
sequence of medical interventions with a marked temporal point process (MTPP)
ii
and embedding this into a Bayesian joint framework where the other components
model longitudinal medical measurements and time-to-event data. Moreover, we pro-
pose a policy gradient method to learn the personalized optimal clinical decision that
maximizes patient survival by interacting the MTPP with the model on clinical ob-
servations while accounting for uncertainties in clinical observations. A signature
application is to schedule follow-up visitations and assign a dosage at each visitation
for patients after kidney transplantation. We demonstrate that the personalized de-
cisions made by our method are interpretable and help improve patient survival, and
provide an R package, doct, that broadly implements our framework.
Lastly, we introduce a Bayesian semiparametric model for learning biomarker
trajectories and change points in Alzheimer’s disease (AD). Through simulation and
real data studies, we show that our model is able to reliably detect a pre-diagnosis
longitudinal change point, evaluate the probability of AD progression, and account
for heterogeneity by clustering subjects using longitudinal and diagnosis time data.
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In Bayesian statistics, we formulate our probabilistic beliefs using prior and pos-
terior distributions. A prior distribution represents to our beliefs about a certain
quantity before we consider information from the data. We then use the data to
update our beliefs and produce a posterior distribution. In the context of statistical
modeling, we are often concerned with the prior and posterior distributions of model
parameters, θ, that model data D. Formally, we compute the posterior distribution










Since the integrating factor is a constant, we can ignore it and formulate the
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For some cases with a carefully chosen prior distribution, the posterior belongs to
the same family of distributions as the prior, and they are referred to as conjugate
distributions. In complex models with many parameters, the posterior distribution of
each parameter cannot be derived in closed form and instead we rely on alternative
Bayesian inference sampling techniques to approximate the posterior distributions
p(θ | D). The primary class of algorithms to solve this issue are Markov chain Monte
Carlo (MCMC) methods, which establish a Markov chain that has the target posterior
distribution as its equilibrium distribution. One of the most commonly used MCMC
methods is the Metropolis-Hastings algorithm, described as follows for a model with
I parameters (θ1, · · · , θI) and N iterations:
In Algorithm 1, the computation for the acceptance probability can be simplified
by carefully selecting the proposal distributions q(θ∗i | θ
(n−1)
i ). For example, if the
full conditional distribution p(θ∗i | θ−i, D) and the prior p(θ∗i ) are conjugate, then
we can choose the proposal distribution to be the full conditional, q(θ∗i | θ
(n−1)
i ) =
p(θ∗i | θ−i, D). This special case of Metropolis-Hastings is called the Gibbs sampling
algorithm and the acceptance probability always equal to one.
In some complicated models, the full conditional and prior distributions for certain
parameters are not conjugate due to multiple types of data. For example, let the
dataset be composed of both survival and longitudinal data, denoted Ds and Dl,
respectively. Then, the acceptance probability in Algorithm 1 for a shared parameter,
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Algorithm 1 Metropolis Hastings
The following illustrates the Metropolis Hastings algorithm to approximate
the target posterior distributions for each parameter, p(θ1 | D), · · · , p(θI |




i for i = 1, · · · , I at arbitrary value, i.e. sample from priors.
2: for n:=1 to N do
3: for i:=1 to I do



































6: Ui ← Uniform(0, 1)
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For these complex datasets, it’s infeasible to construct a model such that the
full conditional distribution, p(θ∗i | θ−i, Ds, Dl), and prior, p(θ∗i ), are conjugate when
considering both types of data. However, the conditional distribution for one data
type, p(θ∗i | θ−i, Dl), can be conjugate with the respective prior. This conjugacy
allows for a prudently selected proposal distribution q(θ∗i | θ
(n−1)
i ) = p(θ
∗
i | θ−i, Dl) to
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p(Ds | θ−i, θ∗i )
p(Ds | θ−i, θ(n−1)i )
.
This trick not only allows for easier computation, but also results in a higher
acceptance probability and improved mixing of the MCMC chain.
1.2 Survival Analysis
In many medical applications, we are interested in studying how certain factors
affect the time to a medical event such as disease progression, organ failure, or patient
death. Such medical events are often denoted “survival events” and the time to a
survival event is referred to as the “survival time” or “event time.” Survival analysis
is used to evaluate the relationship between patient characteristics and survival times.
Let T represent a survival time of interest for a patient and f(t) as its corresponding
probability density function (pdf). Then the cumulative distribution function (cdf)
is F (t) = P (T ≤ t) =
∫ T
0
f(u)du. In survival analysis, we are often interested in
modeling the survival function of T , which is the probability of not experiencing the
survival event at time t:




Another way to model the survival time T is to use a hazard function, which
measures the instantaneous rate of the survival event, given that the survival event
has not yet been observed. Using this definition, we can derive the relationship
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between the hazard function and the density and survival functions:
h(t) = lim
dt→0




P (t < T ≤ t+ dt)





Survival analysis data can be incomplete when certain patients do not observe
a survival event. For example, let us consider a study of cancer patients where the
survival event is death. When the study concludes at time C, some patients may
still be alive and their survival event is unobserved. We refer to this missing data
phenomenon as right-censoring, and the time at which the study ends is the censor
time. The survival data for each patient is composed of Y = min(C, T ) and an
indicator function for censoring, δ = I(T ≤ C). If the patient survival event is
censored, the only information known is that the survival event is larger than the
censor time. Thus, we can write the likelihood of the survival data (Y, δ) as:





Precision Dosing of Intravenous
Busulfan in Allogeneic Stem Cell
Transplantation
2.1 Introduction
Allogeneic stem cell transplantation (allo-SCT) is an established treatment for
various hematologic diseases, including acute myelogenous and lymphocytic leukemia
and non-Hodgkins lymphoma. Intravenous (IV) busulfan has been established as
a desirable component of the preparative regimen for allo-SCT, due to its absolute
bioavailability and dosing accuracy, leading to improved patient survival (Andersson
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et al., 2002; Bredeson et al., 2013; Copelan et al., 2013; Nagler et al., 2013; Wachowiak
et al., 2011). The patient’s busulfan systemic exposure (Bu-SE) represented by the
area under the plasma concentration versus time curve, AUC, is crucial, as serious
adverse events are associated with an AUC that is either very high or too low. Higher
AUC values are associated with neurologic toxicity (grand mal seizures), hepatic
veno-occlusive disease, mucositis, and/or gastro-intestinal toxicity (Dix et al., 1996;
Geddes et al., 2008; Kontoyiannis et al., 2001; Ljungman et al., 1997). Lower AUC is
associated with an increased likelihood of disease recurrence and thus shorter survival
time (Andersson et al., 2017; Bartelink et al., 2009; McCune et al., 2002; Russell et al.,
2013; Slattery et al., 1997).
Consequently, it is important to define an optimal AUC interval of busulfan expo-
sure that maximizes survival while minimizing risk. Studies of fixed-dose oral busulfan
regimens suggest that inter-individual variations in Bu-SE exposure may be as high
as 10- to 20-fold. In contrast, IV delivery of busulfan is more consistent and reliable
for controlling delivered dose (Andersson et al., 2000), and thus is better suited for
obtaining optimal busulfan AUC intervals. Andersson et al. (2002) showed that an
optimal interval of IV Bu-SE had AUC values approximately 950 to 1520 µMol-min
from one representative dose in a typical 16-dose treatment course, or a total course
AUC of 15,200 – 24,400 µMol-min, yielding longer survival times and lower toxic-
ity rates compared with values outside this interval. More recently, Bartelink et al.
(2016) reported that, in children and young adults, the optimal daily AUC range in
a prototype 4-day Bu-based regimen was 78-101 mg*h/L (corresponding to a total
course AUC of about 19,100 – 21,200 µMol-min), regardless of the type or stage of
underlying disease and whether the patients were in complete remission (CR) if they
had an underlying malignancy.
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In this chapter, we account for patient heterogeneity to assess the joint impact
of patient age, CR status, and AUC on patient survival, with the goal to determine
covariate-specific optimal daily AUC intervals. To evaluate possible interactions be-
tween covariates and Bu-SE, and their association with treatment outcome, we an-
alyzed a dataset of 151 patients who underwent allo-SCT for acute myelogenous
leukemia (AML) and myelodysplastic syndrome (MDS). It has been demonstrated
that many different comorbidity conditions may affect the patient’s risk for devel-
oping complications with these procedures (Sorror et al., 2005, 2014). Additionally,
there commonly is a correlation between the severity of comorbidities and patient age.
Therefore, we analyzed the outcome of our patients using age as a continuous covari-
ate. We also included the indicator of whether the patient was in CR or had active
disease at time of allo-SCT, since patients transplanted in CR have, on average, more
favorable outcomes (De Lima et al., 2004; Kanakry et al., 2014). Our goal was to
find patient-specific optimal AUC ranges that maximize expected survival time given
the patient’s age and CR status. The results of this analysis may provide specific
guidelines for so-called “personalized” or “precision” medicine in clinical practice.
Andersson et al. (2002) estimated the optimal AUC range by fitting a Cox pro-
portional hazards regression model for overall survival (OS) time and smoothing a
martingale residual plot, which showed that the hazard of death was approximately
a quadratic function of log(AUC). Bartelink et al. (2016) used a fourth-order polyno-
mial model to estimate the association between AUC and OS. Both of these methods
assumed specific parametric distributions for survival time, and the latter analysis
assumed a specific polynomial function for the relationship between AUC and OS.
For our data set, Figure 2.1 shows histograms and estimated density plots of the
patients’ OS times in weeks, with and without a log transformation of OS. The figure
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clearly presents a long-tailed distribution that might result from a mixture of several
unknown distributions. Alternatively, the long-tailed distribution might be due to
the fact patients who have survived at least four years from transplant are at risk of
death from natural causes, rather than leukemia or transplant related causes. Conse-
quently, the specific models and strong parametric assumptions made by Andersson
et al. (2002) and Bartelink et al. (2016) may not be suitable to fit the current data set
well. In particular, the proportional hazards assumption underlying the Cox model
may not be valid. Even given a survival distribution that fits the data reasonably
well, an additional problem is determining functional relationships between AUC,
prognostic covariates, and the risk of death.
We present a flexible Bayesian nonparametric (BNP) survival regression model to
estimate the relationship between survival time, AUC, and baseline covariates. Based
on our analysis of the allo-SCT dataset, we determined personalized optimal AUC
ranges based on patient’ age and CR status. An important advantage of BNP models
is that they often fit complicated data structures better than parametric model-based
methods because BNP models can accurately approximate essentially any distribu-
tion or function, a property known as “full support.” Another important advantage
of BNP models is that they often identify unexpected structures in a dataset that
cannot be seen using conventional statistical models and methods. BNP models
have been used widely for survival analysis. Hanson and Johnson (2002) proposed a
mixture of Polya tree priors in semiparametric accelerated failure time (AFT) mod-
els, while Gelfand and Kottas (2003) developed the corresponding Dirichlet process
(DP) mixture approach. Zhou and Hanson (2018) presented a unified approach for
modeling survival data by exploiting and extending the three most commonly-used
semiparametric models: proportional hazards, proportional odds, and accelerated
9































Figure 2.1: Histograms of overall survival time in weeks (top) and log overall survival
time (bottom), with nonparametric density estimates.
10
failure time. Despite the flexibility of these approaches for modeling baseline survival
distributions, they are restricted in the way that covariates may affect the baseline
distribution. Fully nonparametric tree-based survival models have been developed,
such as the use of random forests (Ishwaran et al., 2008) and Bayesian additive regres-
sion trees (Sparapani et al., 2016). De Iorio et al. (2009) proposed an unconstrained
survival regression model with a dependent Dirichlet process (DDP) (MacEachern,
1999) prior in order to incorporate covariates in a naturally interpretable way. Xu
et al. (2016) developed a DDP prior with Gaussian process as the base measure, the
DDP-GP model, to evaluate overall survival (OS) times of complex dynamic treat-
ment regimes including multiple transition times. However, a non-trivial limitation
of the DDP-GP model in Xu et al. (2016) is that it gives the same fixed weight to
all covariates, regardless of their numerical domains, when quantifying dependence
between patients. Such a restriction may yield a sub-optimal posterior contraction
rate, causing less accurate estimations (van der Vaart and van Zanten, 2011).
Building on the work in Xu et al. (2016), in this chapter we propose a flexible
survival regression framework by formulating a DDP with a more general covariance
function for the GP prior that includes an individual scale parameter for each co-
variate and additional hyperparameters for model flexibility and robustness. The
proposed model provides easy-to-implement posterior inferences in settings where
the proportional hazards assumption, specific parametric models such as AFT mod-
els, or semi-parametric models may not fit the data well. Currently, the R package
survival, which is limited to such models, remains a standard tool for statistical
and medical researchers. One of the main contributions of this chapter is to provide
a new, easy-to-use R package, DDPGPSurv, that implements the proposed DDP-GP
survival regression model for a broad range of survival analyses. A major goal is
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that DDPGPSurv will become a new standard computational tool for implementing
this generalized DDP-GP to conduct survival analysis in medical research.
The rest of the chapter is organized as follows. In Section 2.2 we review the
motivating dataset. We present the DDP-GP survival regression model in Section
2.3. Section 2.4 gives a brief introduction to the R package DDPGPSurv. Extensive
simulation studies with comparison to alternative methods are conducted in Section
2.5. We analyze our dataset in Section 6, and conclude with a brief discussion in
Section 7.
2.2 Motivating Study
When total body irradiation was replaced with high-dose oral busulfan (Santos
et al., 1983; Tutschka et al., 1987), it quickly became clear that unpredictable, often
lethal, toxicities limited the use of a busulfan-based conditioning program. Several
retrospective studies indicated an association between systemic drug exposure and
clinical treatment outcome (Dix et al., 1996; Slattery et al., 1997). This spawned
an interest in exploring pharmacokinetic dose guidance, but the erratic bioavailabil-
ity of oral busulfan prevented its successful implementation in a prospective fashion.
The advent of IV Busulfan, which guarantees complete bioavailability with absolute
assurance for systemic dose delivery has changed this. Routine application of ther-
apeutic dose guidance for IV busulfan in pre-transplant conditioning therapy now
makes it possible to accurately deliver a predetermined systemic exposure dose in
terms of AUC, thereby optimizing treatment. This is important, since in (myeloid)
leukemia the cytotoxic drug dose and accurate dose delivery are associated with clin-




≤ 25 12 (8%)
26− 35 22 (15%)
36− 45 32 (21%)
46− 55 50 (33%)













Table 2.1: Patient characteristics at time of transplan-
tation.
et al., 2004; Russell et al., 2013). A question that has not yet been resolved satis-
factorily is what optimal systemic exposure dose to target in an individual patient.
To address this decisively, we have retrieved data in The University of Texas MD
Anderson Cancer Center from 151 AML/MDS patients who received a standardized
4-day fludarabine-IV busulfan combination, with both agents administered based on
body surface area. Pharmacological studies of busulfan were performed as an op-
tional procedure, but the information was not used for busulfan dose-adjustments.
The dataset includes overall survival (OS) times and the covariates age, CR status,
and AUC. Table 1 summarizes the characteristics of the study population at baseline.
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2.3 Probability Model
2.3.1 Dependent Dirichlet process-Gaussian pro-
cess prior
Denote the log time to death by Y and censoring time on the log(time) domain by
C, with T = Y ∧C the observed log time of the event or censoring, and δ = I(Y ≤ C).
Indexing patients by i = 1, · · · , n, the observed outcome data for patient i are (Ti, δi),
and we let xi denote the baseline covariate vector, including age, CR status, and AUC.
We construct a Bayesian nonparametric (BNP) survival regression model for F (Y |
x), the distribution of [Y | x], as follows. We start with a model for a discrete random
distribution G(·), then use a Gaussian kernel to extend this to a prior for a continuous
random distribution, and finally we replace the kernel means by a regression structure
to define the desired prior on {F (Y | x), x ∈ X}. The constructions of G(·) and
F (·) are elaborated below, by way of a brief review of BNP models. See, for example,
Müller and Mitra (2013) and Müller and Rodriguez (2013) for more extensive reviews.
First proposed by Ferguson (1973), the Dirichlet process (DP) prior has been
used widely in Bayesian analyses as a prior model for random unknown probability
distributions. A DP(α0, G0) involves a positive scaling parameter α0 and a base
probability measure G0. A constructive definition of a DP is provided by Sethuraman
(1994), the so-called “stick-breaking” construction, given by G =
∑∞
h=1whδθh , where
θh ∼ G0, and wh = vh
∏
l<h(1 − vl) with vh ∼ be(1, α). Here, δθh(·) denotes the
Dirac delta function, which is equal to 1 at θh and is equal to 0 everywhere else. In
many applications, the discrete nature of G is not appropriate. To deal with this, a
DP mixture model extends the DP model by replacing each point mass δ(θh) with
14





2) denotes a normal distribution with mean θh and standard deviation σ.
To include regression on covariates, MacEachern (1999), extended the DP mix-
ture model by replacing each mean parameter θh in the sum with a function θh(x)
of covariates x. This is called a dependent Dirichlet process (DDP), obtained by
assuming the regression model
F (y | x) =
∞∑
h=1
wh N(y; θh(x), σ
2),
where one can specify a stochastic process prior for {θh(x)}. As a default assumption
MacEachern (1999) proposed a Gaussian process (GP) prior. Here, the GP is indexed
by x. Temporarily suppressing the subindex h, a GP prior is characterized by the
marginal distribution for any n-tuple (θ(x1), . . . , θ(xn)) being a multivariate normal
distribution with mean vector (µ(x1), . . . , µ(xn)) and (n×n) covariance matrix with
(i, j) element C(xi,xj), for any set of n ≥ 1 covariate vectors x1, · · · ,xn. We denote
this model by θ(x) ∼ GP(µ,C). Extensive reviews of the GP are given by MacKay
(1999) and Rasmussen and Williams (2006).
In the context of modeling each patient’s transition times between successive dis-
ease states in a dataset arising from multi-stage chemotherapy of acute leukemia, Xu
et al. (2016) modeled {θh(x)} ∼ GP(µh(·), C(·, ·)), h = 1, 2, . . . with µh(xi;βh) =
xiβh and C(xi,x`) = exp{−
∑D
d=1(xid − x`d)2} + δi`J2. Here, D is the dimension of
the covariate vector, with δi` = I(i = `) = 1 if i = ` and 0 otherwise. The term J
2 is
jitter added to provide numerical stability by avoiding singular covariance matrices,
with a small value such as J = 0.1 typically used.
A non-trivial limitation of this covariance function is that it gives the same weight
to all covariates, regardless of their numerical domains, when quantifying dependence
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between patients. This implies that different covariates xd and xd′ contribute the same
to the correlation between patients i and l as long as (xid−x`d)2 and (xid′−x`d′)2 are
the same. Furthermore, without including hyperparameters with prior distributions
in the covariance function, the posterior inference using a Gaussian process prior may
yield a posterior contraction rate that is sub-optimal (van der Vaart and van Zanten,
2011). To avoid these limitations, we extend the DDP-GP model by including an
additional scale parameter, λd, for each covariate xd and also an overall multiplicative













The multiplicative scale parameter σ20 accounts for variability in the data that is not
accommodated by the variance σ2 of the normal component distributions.
The model can be summarized as
p(yi | xi, F ) = Fxi(yi)
{Fx} ∼ DDP-GP
{
{µh}, C;α, {βh}, {λ2d}, σ20, σ2
}
. (2.2)
We use the acronym DDP-GP to refer to the proposed model with the DDP mixture




whN(y; θh(x), σ2) with {θh(x)} ∼ GP(µh(·), C(·, ·)), (2.3)
where h = 1, 2, . . ., µh(xi) = xiβh, and C(·, ·) is defined in (2.1).
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2.3.2 DDP-GP survival regression model
Denote the vector of all model parameters by Θ and the data byDn = {Ti, δi,xi}ni=1.
The likelihood function is the usual form
L(Θ | Dn) =
n∏
i=1
fxi(ti | Θ)δi{1− Fxi(ti | Θ)}1−δi ,
where fx(·) and Fx(·) denote the density and cumulative distribution function of Y
for an individual with covariates x. Given the assumed DDP-GP prior on Fx(·),
shown in (2.2), we complete the model by assuming the priors βh ∼ N(β0,Σ0),
1/σ2 ∼ Gamma(a1, b1), the precision parameter α ∼ Gamma(a2, b2), σ0 ∼ N(0, τ 2σ),
and the covariate scale parameters λd ∼ iid N(0, τ 2), d = 1, · · · , D. Thus, the DDP-




To implement the DDP-GP model, one first must determine numerical values for
the hyperparameters θ∗. We introduce default choices for fixing θ∗ in our DDPGPSurv
package below, although users can define their own preferred values, if desired. We
suggest using an empirical Bayes method to obtain β0 by fitting a normal distribution
for patient response on the log scale, log(Y ) | x ∼ N(xβ0, σ̂2) and assuming Σ0 to be
a diagonal matrix with all diagonal values 10. Once an empirical estimate σ̂2 of σ2
is obtained, one can tune (a1, b1) so that the prior mean of σ
2 matches the empirical
estimate and the variance equals 10 or a suitably large value to ensure a vague prior.
The total mass parameter α in the stick-breaking construction determines the number
of unique clusters in the underlying DP Polya urn scheme. Usually, the DP yields
many small clusters, therefore changing the prior of α does not significantly alter
posterior predictive inference, which we will use for estimating the survival function
and optimal AUC ranges. We assume a2 = b2 = 1 to ensure a vague prior on α.
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Lastly, we assume τ = τσ = 10 so that the ranges of λd’s and σ0 in the covariance
function are large enough to cover variability in the data.
To obtain posterior inference for a DDP-GP survival regression model, we first
marginalize (2.2) analytically with respect to the random probability measures Fx(·).
To do this, we first rewrite (2.3) equivalently as a hierarchical model with a set of
new latent indicator variables γi as
(Yi | γi = h,xi) ∼ N(θh(xi), σ2) and p(γi = h) = wh, (2.4)
for i = 1, · · · , n. If clusters of patients are defined as Sh = {i : θ̃i = θh},
then the γi’s are interpreted as cluster membership indicators. Posterior simula-
tion makes use of these indicators and the vectors θh = (θh(x1), . . . , θh(xn)). Af-
ter marginalization with respect to Fx, we are left with the marginal model for
{γi, θh(xi); i = 1, . . . , n, h = 1, . . .}. We implement posterior sampling based on
the collapsed Gibbs sampler (Escobar and West, 1995) in the R package DDPGPSurv.
Details of the MCMC computations are provided in Section 2.8.
2.3.3 Personalized optimal AUC range estimation
Let ρn = (S1, . . . , SH) denote the partition of the n patients, determined by the
clusters induced by the γi’s. A key advantage of the proposed BNP model is that we
can easily write down the posterior predictive distribution of the outcome Yn+1 for a
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future patient with covariate vector xn+1, given by













The innermost sum averages with respect to the cluster membership for the (n+ 1)st
patient during the MCMC. The term h = H+1 corresponds to the case that this new
patient may form his/her own singleton cluster. The posterior average with respect
to p(ρn | Dn) and p(Θ | ρn,Dn) is evaluated as an average over the MCMC sample.
For the IV busulfan allo-SCT data, x includes the key treatment variable AUC,
which quantifies the patient’s delivered dose of IV busulfan and thus may be targeted
by the treating physician. From (2.5), based on our analysis of the IV busulfan data
using the DDP-GP, we can use the predictive distribution to compute the optimal
AUC for the future patient n+1 as that which maximizes expected log survival time,
ÂUCn+1 = argmaxAUCE(Yn+1 | xn+1,Dn), (2.6)
where xn+1 includes patients’ age, CR status, and AUC. The laboratory-based method
for determining the median specific daily Bu-SE has about a 3% error when sampling
is carried over 12-14 hours (or about 3-4 drug half-lives). However, if sampling is
restricted to 4-6 hours (1.0 - 1.5 drug half-lives), as is done with many PK evaluation
methods, the error increases to at least 6%. Based on these considerations, we de-
cided to use optimal AUC +/- 10% as an reasonable interval for targeting, since it is
not possible to detect any difference in covariate impact on outcome between patients
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with AUC values falling within this narrow Bu-SE interval. Therefore, we define the
optimal AUC interval for future patient n+ 1 as
[
0.9× ÂUCn+1, 1.1× ÂUCn+1
]
,
bearing in mind that ÂUCn+1 depends on the patient’s covariates xn+1.
2.4 R package: DDPGPSurv
One of the main contributions of this chapter is that we have developed an R
package, DDPGPSurv, that implements the proposed DDP-GP model as a general tool
for survival analysis. The functions in the package perform inference via MCMC
simulations from the posterior distributions based on a DDP-GP prior using a col-
lapsed Gibbs sampler (mcmc_DDPGP). The outputs from mcmc_DDPGP are then used
as the inputs for the other functions to evaluate and plot the estimated posterior
predicted density, survival, and hazard functions for new observations/patients. The
package also includes a function for evaluating posterior mean survival for specified
values of the covariate vector. For example, this allows the user to determine the
optimal value of a specific covariate (with the other covariates fixed) that maximizes
posterior expected survival time. The R package DDPGPSurv can be downloaded from
https://cran.r-project.org/web/packages/DDPGPSurv/index.html.
Current standard methods for survival analysis typically involve the Kaplan-Meier
(KM) estimator for unadjusted survival times with independent right censoring, ac-
celerated failure time (AFT) models, or the Cox proportional hazards (PH) model.
The KM estimator is a non-parametric statistic and is constructed using a finite num-
ber of conditional probabilities of survival at successive time intervals. To analyze
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the effects of specific covariates using the KM estimator, the most common approach
is simply to compute the KM for particular patient subsets that may be defined from
x, which reduces reliability. AFT regression models are fully parametric, which may
be problematic if the baseline hazard function does not fit the specified AFT distribu-
tion. Comparisons between the DDP-GP and AFT models via simulations show that
the DDP-GP is more robust, with much more accurate predictions across a range of
various distributions (Weibull, lognormal, exponential). That is, if the distribution
selected for the AFT model does not match the truth, the predictions will be inaccu-
rate. The Cox model, which is semi-parametric, relies on the PH assumption, which
states that the each covariate has a constant effect on the hazard function that does
not vary over time. This assumption may not always be true, and it is not required by
the DDP-GP model. Additionally, as with any BNP model, the DDP-GP accommo-
dates irregularly shaped survival distributions, for example having multiple modes.
Thus, the DDP-GP, implemented by the DDPGPSurv package, provides many advan-
tages over these conventional methods, including robustness and accuracy across a
wide range of possible distributions.
2.5 Simulation Studies
We conducted simulation studies to evaluate the DDP-GP model in terms of es-
timation of survival densities and optimal personalized AUC ranges, with the data
simulated to mimic the structure of the allo-SCT dataset. We generated T=survival
time, the covariates x1 = age, x2 = AUC, and x3 = CR status for each patient,
as follows. Let LN(m, s) denote a log normal distribution with location and scale
parameters m and s, and let xi = (xi,1, xi,2, xi,3) denote the covariates for patient i.
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Patients’ ages and AUC values were sampled with replacement from the actual ages
and AUC values in the allo-SCT dataset. We generated patients’ CR statuses as in-
dependently and identically distributed (i.i.d.) binary variables from a Bernoulli(0.5).
We simulated the Yi’s from a lognormal distribution, Yi | xi ∼ LN(µ(xi), σ20), where
the location parameter is the following function of xi,
µ(xi) = 4−0.1xi,1 +0.7xi,2 +0.3xi,3−0.07x2i,2−0.1xi,1xi,2 +0.2xi,2xi,3−0.18xi,1xi,2xi,3,
for i = 1, · · · , n, and σ0 = 0.4. We deliberately designed the form of µ(xi) based
on clinical knowledge, including a quadratic term for AUC to reflect the fact that a
Bu-SE that is either too high or too low is associated with shorter survival time. We
also included interaction terms between AUC and covariates so that the relationship
between survival and AUC may vary depending on each patient’s age and CR status.
We considered two scenarios, one with n = 200 observations without censoring
and the other with n = 200 and 25% censoring. For each scenario, B = 100 trials
were simulated, and the proposed DDP-GP survival regression model was fit to each
simulated dataset. The MCMC sampler was implemented for posterior inference and
run for 5,000 iterations with an initial burn-in of 2,000 iterations, thinned by 10.
We used the R package coda (Plummer et al., 2006) to check convergence, and both
traceplots and autocorrelation plots (not shown) to check mixing of the Markov chain,
which showed no convergence problems.
2.5.1 Survival density estimation
For simulated trials indexed by b = 1, · · · , B, let Sb(t | x) = p(Yn+1 ≥ t | xn+1 =
x,Dn) denote the posterior predicted probability that a future patient n + 1 with
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covariate x in trial b survives beyond time t. To estimate Sb(t | x) using our package
DDPGPSurv, we first run the MCMC using the function mcmc_DDPGP. Then, the output
from the function mcmc_DDPGP serves as the input to the function DDPGP_Surv, which
returns the mean and 95% credible intervals for the survival function across the saved















For comparators, we considered six alternative methods. First, we fit AFT regres-
sion models using either lognormal or Weibull distributions by assuming
log(Yi) = β0 + β1xi,1 + β2xi,2 + β3xi,3 + β4x
2
i,2 + β5xi,1xi,2 + β6xi,2xi,3 + β7xi,1xi,3 + σεi.
(2.7)
Here, assuming a normal distribution on εi implies that Yi follows a lognormal distri-
bution, while the extreme value distribution assumption on εi implies that Yi follows
a Weibull distribution. We also considered two flexible semiparametric survival meth-
ods that model the baseline survival using a Polya Trees (PT) prior (Hanson and John-
son, 2002) or a transformed Bernstein polynomials (TBP) prior (Zhou and Hanson,
2018), respectively. Both models were implemented in the R package spBayesSurv
(Zhou et al., 2018) . We assumed the AFT regression model as the frailty model in
both the PT and TBP methods with the same setup as in (2.7). Lastly, we com-
pared the proposed DDP-GP model to two fully nonparametric survival models using
random forests (RF) (Ishwaran et al., 2008) and Bayesian additive regression trees
(BART) (Sparapani et al., 2016). We used the R packages randomForestSRC (Ish-
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waran and Kogalur, 2007) and BART (McCulloch et al., 2018) to implement the RF
method and the BART method, respectively.












the maximum likelihood estimates (MLEs) obtained under each of the two AFT mod-
els, and the estimated survival curves under the PT, TBP, BF, and BART methods.
In each scenario, the true curve is given as a solid black solid line and the posterior
mean survival function under the DDP-GP model as a solid grat line with point-wise
95% posterior credible bands as two dotted gray lines. In both scenarios, the DDP-GP


















































(a) n = 200 without censoring (b) n = 200 with 25% censoring
Figure 2.2: Survival function estimates for the simulated data, with survival time
on the log scale. True survival functions are in black compared with the estimated
posterior mean survival functions under the DDP-GP model with point-wise 95%
credible bands as two dashed lines, for n = 200 (left) and n = 200 with 25% censoring
(right). For comparators, we also show the survival function estimates under AFT
regression models using the lognormal and Weibull distributions, TBP, PT, RF, and
BART.
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model based estimate, as well as the RF and BART methods, reliably recovered the
shape of the true survival function, while the four other methods (AFT Lognormal,
AFT Weibull, TBP, and PT) showed substantial bias.
2.5.2 Personalized optimal AUC estimation
For the simulated data, we next evaluated the ability of the DDP-GP survival
regression model to estimate optimal personalized AUC ranges, computed by (2.6).
This estimation can be performed by the function DDPGP_meansurvival in our R
package DDPGPSurv. This function takes the output from mcmc_DDPGP and calculates
the posterior mean survival times and 95% credible intervals for patients of interest.
Figure 2.5 compares the simulated true optimal AUC and the optimal AUC range
estimates for a 30-year old patient with two different CR statuses, under each of seven
models: the DDP-GP model, and the lognormal or Weibull AFT models in (2.7),
TBP, PT, RF, and BART. Since the RF and BART methods do not have closed-
forms for mean survival times and only provide the estimated survival probabilities
at the time points observed in the original data, we estimated the mean survival
time as the area under the survival curve in the interval (0, tmax), where tmax is the
largest observed time point in the data. In Figure 2.5, the numbers in parentheses
in the legend represent the simulated true optimal AUC and the optimal AUC range
estimated by the DDP-GP survival regression model. The figure shows that the DDP-
GP model accurately estimates the mean survival function and identifies the optimal
AUC, with the simulated true AUC being in the estimated optimal AUC range. In
contrast, the mean survival functions and the optimal AUC estimates given by the
AFT models, PT, and TBP are considerably different from the simulation truth.
For instance, when CR=No with 25% censoring, the AFT models with lognormal
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or Weibull distributions estimate the optimal AUC to be 4.4 and 4.5, respectively,
while the true AUC is 3.9. While the RF and BART methods are able to accurately
estimate the survival function, the estimates of mean survival are biased, especially
when the data are censored.
In summary, the DDP-GP is more robust than alternative methods in the sense
that it can better fit the survival functions and more accurately estimate personal-
ized optimal AUC ranges, even while only including the main effects (β0 + β1xi,1 +
β2xi,2 +β3xi,3) in the mean of the Gaussian process prior. In contrast, the alternative
parametric and semiparametric models which do not perform as well as the DDP-GP,
include not only main effects but also quadratic terms and interactions between co-
variates as in (2.7). This illustrates an important advantage of the DDP-GP model.
It allows one to include covariates as simple linear combinations, but still is able to
identify quite general interactions that are not limited to conventional multiplicative
interaction terms, such as β1AUC × age + β2AUC ×CR, that typically are included
in the linear components of conventional Cox or AFT models. Such a construction is
extremely useful especially when the covariates are high-dimensional, in which case
including all the interactions among covariates in the regression model is infeasible.
2.5.3 Additional Simulation Studies
In this additional simulation study, we evaluate whether the proposed DDP-GP
model is stable under a setting with a larger number of covariates and show the
necessity of the covariate-specific scale parameters λd’s in the covariance function.
For this purpose, we compared our DDP-GP model to a simpler version with only
one single scale parameter, λsingle, called naive DDP-GP. The naive DDP-GP has an
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Let LN(m, s) denote a lognormal distribution with location and scale param-
eters m and s. We assume each patient i has a 10-dimensional covariate xi =
(xi,1, xi,2, xi,3, xi,4, xi,5, xi,6, xi,7, xi,8, xi,9, xi,10). Patients’ ages (xi,1) and AUC (xi,2)
values were sampled with replacement from the ages and AUC’s given in our IV
busulfan allo-SCT dataset. We generated the patients’ CR status (xi,3) as a bi-
nary variable from a Bernoulli(0.5), which also mimics the IV busulfan dataset. The
remaining seven covariates were independently sampled from a standard normal dis-
tribution N(0, 1). We simulated the Yi’s from a lognormal distribution with location
parameters that vary with xi, where the covariates xi,9 and xi,10 were not related to
the response.
Yi | xi ∼ LN(µ(xi), σ20),
µ(xi) = 4− 0.1(xi,1− xi,4 + 1) + 0.7(xi,2 + xi,5− 1) + 0.3(xi,3− xi,6)− 0.07(x2i,2 + x2i,7)
−0.1xi,1xi,2(xi,8 + 0.5) + 0.2xi,2xi,3 − 0.18xi,1xi,2xi,3,
for i = 1, · · · , n, and σ0 = 0.4.
The survival density estimation was computed for two scenarios: one scenario
with n = 200 observations without censoring and the other with n = 200 and 25%
censoring. For each scenario, B = 100 trials were simulated, then the DDP-GP model
and the naive DDP-GP model were fitted to each trial with 5,000 MCMC iterations
and 2000 burn-in. From Figure 2.3, we can see that both models are able to recover
the shape of the true survival function, with the naive DDP-GP model having a
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slightly larger credible interval.












































Figure 2.3: Survival function estimates for the simulated data, with survival time
in log scale. True survival functions are in black and the estimated mean survival
functions under the naive DDP-GP model and the DDP-GP model are in brown and
green, respectively, with the point-wise 95% credible bands as the dotted lines, for
n = 200 (left) and n = 200 with 25% censoring (right).
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Figure 2.4 compares the simulated true optimal AUC and the optimal AUC range
estimates under the DDP-GP model and the naive DDP-GP for a patient with the
following covariate:
xi,1 = −1.14706 (30-year old)
xi,3 = 0 (CR=No)
xi,4 = xi,5 = xi,6 = xi,7 = 0
xi,8 = 0.5, xi,9 = xi,10 = 1.
In Figure 2.4, the numbers in parentheses in the legend represent the simulated
true optimal AUC and the optimal AUC range estimated by the DDP-GP model.
We can see that the proposed DDP-GP model recovers the true mean survival curve
accurately under this complex setup with 10 covariates. In contrast, the naive DDP-
GP model yields a poor estimate for the mean survival. Therefore, the proposed
DDP-GP model is robust under a large number of covariates. Also, the inclusion of
the covariate-specific scale parameters λd’s in the model are necessary for accurate
survival estimation and mean survival estimation.
2.6 IV busulfan Data Analysis
While an optimal AUC interval has been determined previously for use in all
patients (Andersson et al., 2002), the underlying statistical analyses motivating this
assume homogeneity, and thus do not allow the possibility that the optimal interval
may vary non-trivially with patient characteristics. Here, we approach the problem
differently by estimating mean survival time as a function of (age, CR status, AUC),
allowing the possibility that the effect of AUC on survival may vary with age and
CR.
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Figure 2.4: Optimal AUC estimation for the simulated data, with both survival time
and AUC on the log scale. True mean survival functions versus AUC are in black
and the estimated mean survival functions under the DDP-GP model are in dark
gray with point-wise 95% credible bands as two dotted dark gray lines for n = 200
(left) and n = 200 with 25% censoring (right). Similarly, the estimated mean survival
functions under the naive DDP-GP model are shown in light gray with point-wise
95% credible bands.
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(a) n = 200 without censoring, CR=No (b) n = 200 with 25% censoring, CR=No


































































(c) n = 200 without censoring, CR=Yes (d) n = 200 with 25% censoring, CR=Yes
Figure 2.5: Optimal AUC estimation for the simulated data, with both survival
time and AUC on the log scale. True mean survival functions versus AUC are in
black compared with estimated mean survival functions under the DDP-GP model
with point-wise 95% credible bands as two dotted lines for n = 200 (left plots) and
n = 200 with 25% censoring (right plots). For the comparators, we also show the
mean survival function estimates under AFT regression models using the lognormal
and Weibull distributions, TBP, PT, RF, and BART. The numbers in parentheses in
the legend are the true and estimated optimal AUC values.
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The AUC values in our analysis are in units of thousands of mean daily µM/∗min.
An initial analysis of the IV Bu dataset using Kaplan-Meier estimates is given in
Figure 2.6. We divided patients into four groups based on CR status and age, di-
chotomized as being above or below the median age of 49, and plotted their survival
probabilities. Figure 2.6 illustrates the well-known fact that being in CR at transplant
yields higher survival probabilities. Similarly, younger patients are also expected to
have higher survival probabilities. The p-value obtained from the log rank test com-
paring the survival distributions between the four groups is significant, indicating
that CR and age are important covariates for any survival regression model. The
cut-off 49 for dichotomizing age was chosen for convenience, however, as is commonly
done in survival analyses. In addition to loss of information about the joint effect of
age and CR status on survival caused by dichotomizing age, the reliability of each
Kaplan-Meier estimate is reduced because it is based on a subsample.
We fit the DDP-GP survival regression model to the allo-SCT dataset with 10,000
Gibbs sampler iterations and a burn-in of 5,000 iterations. The estimated posterior
survival distributions with 95% credible intervals under the DDP-GP for patients
with different CR statuses and ages 30, 40, 50, or 60, given AUC=5, are shown in
Figure 2.7, respectively. For each (CR status, age) combination, the optimal AUC
range is defined as the AUC value that maximizes estimated posterior mean survival,
± 10%. Given CR status and AUC, Figure 2.7 shows that the estimated posterior
mean survival function decreases for older patients, agreeing with what was seen in
the preliminary Kaplan-Meier estimates.
For the eight combinations of CR status and Age, we calculated predicted pos-
terior mean survival time as a function of AUC, to address the primary goal of the
analyses. These plots are given in Figure 2.8. Our analyses confirm the existence,
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CR = No, Age ≥ 49
CR = No, Age < 49
CR = Yes, Age ≥ 49
CR = Yes, Age < 49
Log rank p−val: 3.94 × 10−5 
Figure 2.6: Kaplan Meier Plots. The time in weeks (log scale) versus probability
of survival for four different groups are plotted. The p-value from the log rank test
for comparison between the survival distributions between the four groups is given at
the top of the figure.
33














































Figure 2.7: Estimated survival functions under the DDP-GP survival regression
model for patients with different CR status (Yes or No) and ages (30, 40, 50, 60).
The patients are assigned AUC=5. The dashed lines represent the point-wise 95%
credible intervals for each survival curve.
for each combination of CR status and Age, of an optimal AUC range that yields
higher expected survival times compared to an AUC that is either below or above
the optimal range. A very important inference is that these optimal AUC ranges
differ substantially between many of the (CR status, Age) combinations. This has
extremely important therapeutic implications when choosing an individual patient’s
targeted AUC. For example, the optimal AUC interval for a patient not in CR with
Age=50 is 4.7 ± 0.47 = [4.23, 5.17] compared with the optimal interval 5.8 ± 0.58
= [5.22, 6.38] for a patient in CR with Age=40. Since these intervals are disjoint,
they suggest that these two patients should have very different targeted AUC values
to maximize their expected survival times.
In contrast with our inferences, (Bartelink et al., 2016) concluded that CR sta-
tus has a negligible effect on the optimal AUC. However, the results reported by
Bartelink et al. (2016) were based on data from a large number of different medical
34
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Figure 2.8: Mean log survival time estimates under the DDP-GP model, as a func-
tion of AUC, for each of eight (CR status, Age) combinations. The light gray area
in each plot represents the 95% credible interval for estimated mean survival, and
the tick marks on the horizontal axis (rug plot) indicate the AUC values for patients
in the data set. The red area bounded by dashed lines represents the optimal AUC
range, defined as the estimated mean ±10%.
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centers, many different pretransplant conditioning regimens were used, the PK-data
were obtained from different laboratories, with a very heterogeneous pediatric patient
population having a large number of different diagnostic categories, including patients
with malignant and non-malignant genetic disorders. In contrast, our analyses are
based on a much more homogeneous dataset. Our results indicate that CR status is
an important covariate, and that the optimal dose of AUC is higher for patients who
are in CR at transplant. Furthermore, the increased optimal AUC for patients in
CR at transplant versus patients not in CR is much larger in older patients, whereas
these differences appear negligible in adolescents or young adults, similar to what was
reported by Bartelink, et al. (2016). Our results also demonstrate that, across all
ages, mean survival time for patients in CR is larger compared with those not CR.
To further illustrate how the optimal AUC ranges change with both CR and Age,
we plotted the optimal AUC ranges as Age is varied continuously, for CR=Yes and
CR=No, in Figure 2.9. The negative association between optimal AUC and Age
is clearly shown by this figure. It also shows that, while CR status has virtually no
effect on the optimal AUC interval for very young patients with Age ≤ 28, the optimal
AUC for patients in CR at transplant is increasingly higher as Age increases, with
the optimal intervals for CR = Yes versus CR = No becoming completely disjoint for
patients above 55 years of age. Thus, the lower portions of the curves in Figure 2.9
for Age ≤ 28, agree with the conclusion of (Bartelink et al., 2016) for pediatric and
adolescent patients, while the higher portions for Age > 28, provide news insights.
Again, this demonstrates the importance of considering both CR status and Age when
planning a targeted AUC for a patient with a diagnosis of AML or MDS.
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Figure 2.9: Optimal AUC ranges versus age given CR status. The blue and red
lines represent the optimal AUC for CR=Yes and No, respectively. The optimal AUC
ranges are represented by the shaded regions above and below the optimal AUC.
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2.6.1 Comparison Models
We compare the mean survival estimates under the DDP-GP with those produced
by the PT, TBP, RF, and BART, shown in Figures 2.10-2.13 respectively. For the
semiparametric models (PT and TBP), we can see that the optimal AUC decreases
as patient age increases, and is larger for CR=Yes comparing to CR=No. However,
most combinations of CR status and Age do not present quadratic patterns, which
do not agree with the clinical knowledge.
The nonparametric models (RF and BART) produce very noisy results, leading to
difficult clinical interpretations. This may be caused by the limitation of the RF and
BART methods mentioned in Section 5 of the main manuscript that they only provide
the estimated survivals at the time points observed in the original data, leading to
potential bias in estimating the mean survival time.
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Figure 2.10: Mean survival time estimates under the PT survival model, as a
function of AUC, for each of eight (CR status, Age) combinations. Mean survival
time is in the log scale. The gray area in each plot represents the 95% credible
interval for estimated mean survival, and the tick marks on the horizontal axis (rug
plot) indicate the AUC values for patients in the data set.
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Figure 2.11: Mean survival time estimates under the TBP survival model, as a
function of AUC, for each of eight (CR status, Age) combinations. Mean survival
time is in the log scale. The gray area in each plot represents the 95% credible
interval for estimated mean survival, and the tick marks on the horizontal axis (rug
plot) indicate the AUC values for patients in the data set.
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Figure 2.12: Mean survival time estimates under the RF survival model, as a
function of AUC, for each of eight (CR status, Age) combinations. Mean survival
time is in the log scale. The tick marks on the horizontal axis (rug plot) indicate the
AUC values for patients in the data set.
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Figure 2.13: Mean survival time estimates under the BART survival model, as a
function of AUC, for each of eight (CR status, Age) combinations. Mean survival time
is in the log scale. The gray area in each plot represents the 95% credible interval for
estimated mean survival, and the tick marks on the horizontal axis (rug plot) indicate
the AUC values for patients in the data set.
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2.7 Conclusions
We have proposed an extended Bayesian nonparametric DDP-GP model for sur-
vival regression having a generalized covariance structure, studied it by simulation,
and applied it to estimate personalized optimal dose intervals for IV busulfan in allo-
SCT for AML/MDS. Our simulations, constructed to mimic the dataset, show that
the DDP-GP model provides more accurate survival function estimates and optimal
AUC range estimates compared with conventional parametric to AFT models. Our
analyses of the IV busulfan allo-SCT dataset identified optimal AUC intervals, vary-
ing with the patient’s CR status and Age, that previously have not been known for
this treatment. Our results may have profound therapeutic implications, since they
provide a basis for personalized medicine by enabling physicians to prospectively as-
sign an optimized therapeutic target interval for each patient based on his/her CR
status and age.
More generally, we have developed an R package, DDPGPSurv, that implements
the DDP-GP model for a broad range of survival regression analyses. While the
DDP-GP is more complex than conventional survival regression models, its robust-
ness and broad applicability make it an attractive methodology for survival analysis.
The DDP-GP based data analysis reported here, while important in its own right,
identified a nonlinear three-way interaction between age, CR status, and AUC in their
joint effect on survival time, as shown by Figures 6 and 7. This pattern was identified
despite the fact, noted above, that only the main effects were included in the mean
of the Gaussian process prior via the linear term β0 + β1Age+ β2CR+ β3AUC. This
is because the DDP-GP is essentially a mixture model, hence it can identify complex
patterns in the data that may be missed by conventional models. For the allo-SCT IV
busulfan data, this may be related to the multi-modality of the survival time distri-
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bution, seen in Figure 1. This illustrates the practical advantage that, when applying
the DDP-GP, one need not guess or search for complex patterns in the linear term
of the covariates, as is done routinely when applying conventional survival regression
models.
2.8 Posterior Inference Details
The following section summarizes the generalized DDP-GP model and contains
derivations for the Gibbs sampling steps.
2.8.1 Probability Model
For each patient i, i = 1, . . . , n, denote Yi and xi to be the log survival time and
patients’ covariates. Let Ti = min(Yi, Ci), where Ci is the censoring time for patient
i. Denote δi = I{Yi≤Ci}. Let f(y), F (y) and S(y) be the probability density function,
the distribution function, and the survival function of Y , respectively.
Denote Θ the collection of all model parameters and Dn = {Ti, δi,xi}ni=1, the
likelihood function is
L(Θ | Dn) =
n∏
i=1
fxi(ti | Θ)δiSxi(ti | Θ)1−δi ,
where fx(·) and Sx(·) denote the density and the survival function of an individual
with covariate x.
We assume the Dependent Dirichlet Process (DDP) mixture model for F :











vh ∼ Beta(1, α).
For each h, θh is sampled from a Gaussian Process:
{θh(x)} ∼ GP (µh(·), C(·, ·))













where J usually takes a small value (e.g., J = 0.1).
2.8.2 Collapsed Gibbs Sampler
We use ri = h to indicate that ith patient is assigned to hth cluster. Let H be the
number of clusters, nh be the number of patients in cluster h, and X = (x1, . . . ,xn)
′.
Also, we denote θh = (θh(xi), . . . , θh(xn)).
Since
θh ∼ GP (Xβh, C(·, ·)), βh ∼ N(β0,Σ0),
marginalizing βh leads to
θh ∼ GP (Xβ0, XΣ0X ′ + C)
1. Update ri and θi | θ−i, ·.
• When δi = 1,
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p(ri = h | ·) ∝
 n
−
h φ(ti; θh(xi), σ
2) h ≤ H−,
αφ(ti;uXβ0,u(XΣ0X + C)u
′ + σ2) h = H− + 1.
Here u = (u1, . . . , un) with the element ui = 1 and all other elements
being 0; n−h is the number of patients assigned to the hth cluster after
taking out the ith patient; H− is the number of clusters after taking out
the ith patient. φ refers to the normal distribution PDF, while Φ refers to
the normal distribution CDF.
• When δi = 0,
p(ri = h | ·) ∝
 n
−
h (1− Φ(Ci; θh(xi), σ2)) h ≤ H−,
α(1− Φ(Ci;uXβ0,u(XΣ0X + C)u′ + σ2)) h = H− + 1.
Once ri has been sampled, we impute yi from a left truncated normal distribu-
tion, that is pri left truncated at Ci:
pri ∝
 N(θri , σ
2) h ≤ H−,
N(0, σ2 + Ai) h = H
− + 1,
where A = XΣ0X + C and Ai is the (i,i)-th element of A.
Then,
p(θi | ri = h,θ−i, ·) =
 δθh h ≤ H
−
p(θi | yi, G0) h = H− + 1.
46
Here











p(βh | ·) ∝ p(θh | X,βh)p(βh)
∝ exp{−1
2





p(βh | ·) ∼ N((Σ−10 +X ′C−1X)−1(X ′C−1θh + Σ−10 β0), (Σ−10 +X ′C−1X)−1).
3. Update θh = (θh(xi), . . . , θh(xn))




Let Yh be the vector whose entries are the survival times for patients who are
assigned to the hth cluster, i.e., ri = h. Let nh = #{i : ri = h}. Denote U to
be an nh × n matrix: if patient i is the jth element of cluster h, then Uji = 1;
otherwise 0. We have
p(θh | ·) ∝ exp{−
1
2
[(θh −Xβh)′C−1(θh −Xβh) +








































where the prior for σ2 is IG(a1, b1).
5. Update σ0 and λd






Here C is a matrix with σ0 as a parameter in each matrix element. Since there is
no closed form for the posterior distribution of σ0, we use a Metropolis-Hastings
step to update σ0. Similarly for λd, d = 1, · · · , D. Here D represents the total
number of covariates. i.e., the dimension of xi.
6. Update α
The prior for α is Gamma(a2, b2). We generate a latent variable η, conditioning
on α and the number of patients,
η | α, n ∼ Beta(α + 1, n).
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Then,
α | η,H ∼ a2 +H − 1
a2 +H − 1 + n(b2 − log{η})
Ga(a2 +H, b2 − log{η})
+
n(b2 − log{η})
a2 +H − 1 + n(b2 − log{η})
Ga(a2 +H − 1, b2 − log{η}).
2.8.3 Predictive Inference























Regimes in Continuous Time: A
Bayesian Joint Model for
Optimizing Clinical Decisions with
Timing
3.1 Introduction
In biomedical applications involving long-term personalized care of patients with
chronic health conditions (e.g., diabetes, HIV infections, and chronic kidney dis-
eases), treatments often include a sequence of decision making and must be adaptive
to the uniquely evolving disease progression of each patient. Such scenarios are called
dynamic treatment regimes (DTRs). Patients with chronic diseases are usually re-
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quired to follow up with their physicians from time to time and their clinical data
are recorded longitudinally. Based on these clinical observations, physicians make
clinical decisions such as scheduling follow-up visitations and prescribing the right
dosages to optimize patient outcomes given a patient’s individual characteristics and
treatment history at each clinic visitation. This chapter develops a Bayesian joint
framework consisting of a generative probabilistic model for clinical decisions with
timing and a model for clinical observations (e.g., longitudinal clinical measurements
and time-to-event data): these two models share certain structures and parameters in
order to capture the mutual influence between the clinical observations and decisions.
Furthermore, we propose an optimization method that allows the decision model, by
interacting with the other parts of the joint framework, to learn to make the personal-
ized optimal clinical decision at the right time. Such a joint model and the proposed
optimization method will be useful in many biomedical applications. We elaborate on
one signature application in section 3.1.1, explain why existing methods won’t work
well on it in section 3.1.2, and then give an overview of our method and its technical
novelty in section 3.1.3.
3.1.1 A signature application
A signature medical application of the proposed method would be the kidney
transplantation—the most common type of organ transplantation and the primary
therapy for patients with end-stage kidney diseases (Arshad et al., 2019). Compared
to dialysis, kidney transplantation improves patients’ long-term survival and quality
of life but with a lower healthcare cost (Jarl et al., 2018). Despite significant ad-
vances, a number of complications after surgery still represent important causes of
morbidity and mortality for kidney transplant recipients, such as infection, stroke,
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and graft failure (Bicalho et al., 2019; Lamb and Lodhi, 2011). To prevent graft
rejection, patients are usually hospitalized for a few days initially to monitor signs
of complications, then required to have frequent checkups at an outpatient center
after being released. At each visitation, they are administered immunosuppressive
drugs, such as tacrolimus, to keep their immune systems from attacking and rejecting
the new kidney (Kasiske et al., 2010). One crucial medical decision is to schedule
the patients’ post-transplantation follow-up visitations. While follow-up visitation
frequency varies from 0-12 months (Israni et al., 2014), patients with stable kidney
function usually have less frequent follow-ups compared to non-stable patients. An-
other medical decision is to determine the right dosage of tacrolimus at each follow-up
visitation since a dosage that is either very high or too low may cause serious adverse
events. Higher tacrolimus levels have been reported to associate with adverse effects
such as neurotoxicity, nephrotoxicity, and cancers (Naesens et al., 2009); while lower
tacrolimus levels are associated with an increased likelihood of graft rejection (Staatz
et al., 2001). Therefore, optimizing personalized follow-up schedules and prescribing
the right dosage of tacrolimus tailored to each patient at each visitation (i.e., precision
medicine) are critical and can have a significant impact on patients’ survival.
Large-scale kidney transplantation databases, such as French computerized and
validated data in transplantation (DIVAT), provide us opportunities and challenges to
determine personalized optimal follow-up schedules and tacrolimus dosages. DIVAT
is a database storing medical records for kidney transplantation in several French
hospitals (e.g., Nantes, Paris Necker). Data are collected from the date of transplan-
tation until the graft failure, defined as either returning to dialysis or death with a
functioning graft. At each scheduled follow-up visitation, patients’ creatinine levels,
an important biomarker for measuring kidney function, are collected longitudinally
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to determine the next follow-up time and assign dosages by physicians. For exam-
ple, Figure 3.1 presents one randomly selected patient’s longitudinal creatinine levels,
tacrolimus dosages versus his/her follow-up visitations from DIVAT. In the first sev-
eral visitations after kidney transplantation, this patient’s creatinine levels were high,
indicating the kidney was not functioning well, therefore, the physician scheduled
a high frequency of follow ups and prescribed high dosages of tacrolimus. As time
went by, this patient’s kidney function became stable indicated by slowly decreasing
creatinine levels, then the prescribed tacrolimus dosages were also slowly decreasing
accompanied with a decreasing frequency of visitations. For patients with kidney
transplantation, a major clinical outcome of interest is the graft survival time, de-
fined as the time between the transplantation and the first graft failure. Follow-up
schedules and tacrolimus dosages should be made for the sake of maximizing patients’
graft survival time.
3.1.2 Why not use existing methods?
Although many statistical and machine learning DTR methods have been devel-
oped to optimize sequential clinical decisions (Chakraborty, 2013; Laber et al., 2014;
Luckett et al., 2019; Murphy et al., 2003; Xu et al., 2016), they don’t model, and thus
can’t optimize, the timing of clinical decisions. Most DTR methods regard treatment
schedules as known a priori and only learn to adjust other clinical decisions. For ex-
ample, Xu et al. (2016) developed a Bayesian nonparametric approach building upon
a dependent Dirichlet process and a Gaussian process to determine the optimal treat-
ment regimen containing a front-line chemotherapy and a salvage treatment for acute
myelogenous leukemia patients. However, the timing of the salvage treatment was












































































Figure 3.1: Example data for one patient’s creatinine and tacrolimus levels on a log
scale over time. The points represent actual visitations.
or achieved complete remission first then relapsed. Clifton and Laber (2020) reviewed
the use of Q-learning, a general class of reinforcement learning methods, in estimat-
ing optimal treatment regimens taking the timing of the treatment as given. Guan
et al. (2019) attempted to optimize treatment schedules: they developed a Bayesian
nonparametric method that learns to recommend a regular recall time for patients
with periodontal diseases. However, their method only picks the recall time out of
a few pre-defined choices (e.g., 3 months, 6 months, and 9 months) and thus is not
applicable to complicated scenarios like the one introduced in section 3.1.1: at each
visitation after kidney transplantation, the next visitation time has to be carefully
scheduled given the current clinical measurement in order to maximize the patient’s
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health outcome. For instance, when patients’ kidney function is relatively stable,
they should be instructed to wait longer until the next visitation compared to those
who are less stable.
3.1.3 Why use our method?
To the best of our knowledge, the proposed approach is the first general methodol-
ogy for estimating personalized optimal clinical decisions with timing. The method is
cutting-edge because (1) we build a generative probabilistic model that properly han-
dles clinical decisions with timing; (2) we embed this decision model into a Bayesian
joint framework that also models clinical observations; (3) we train it using a policy
gradient method to generate personalized treatment schedules alongside other clinical
decisions that would optimize patients’ health outcomes.
Our decision model is a marked temporal point process (MTPP) (Aalen et al.,
2008), which is a natural tool to model discrete events in continuous time. It has
been widely applied and become increasingly popular in various domains, including
social science (Butts and Marcum, 2017), medical analytics (Liu et al., 2018), finance
(Hawkes, 2018), and stochastic optimal control (Tabibian et al., 2019). In our example
application of section 3.1.1, each follow-up visitation is an event: the visitation time
is assumed to be stochastically scheduled according to the probability distribution
characterized by the proposed MTPP; and the assigned tacrolimus dosage, when the
visitation happens, is treated as the corresponding “mark.”
The proposed MTPP for clinical decisions is then embedded into a Bayesian joint
framework where it shares certain structures and parameters with the other compo-
nents modeling clinical observations, including longitudinal creatinine measurements
and patient survival in the example application of section 3.1.1. Such design allows
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our model to capture the complicated mutual influence between clinical observa-
tions (e.g., creatinine levels) and decisions (e.g., treatment schedules and tacrolimus
dosages).
Next, we fit the proposed Bayesian joint model on clinical observations and de-
cisions to the data, and then let the decision model interact with the observation
model in an optimization procedure. This technique is known as “reinforcement
learning” (Sutton and Barto, 2018): the decision model (also called the “policy”)
is reinforced, by the feedback from the observation model (also called the “environ-
ment”), to give personalized optimal treatment schedules and dosages that would
improve the expected health outcome for each patient. The Bayesian nature of our
joint framework allows the learning to account for parameter uncertainties in the ob-
servation model. Figure 3.2 illustrates the proposed Bayesian joint framework and
how its components interact. The R package doct (short for “Decisions Optimized in
Continuous Time”) implementing the proposed model and algorithm is available at
https://github.com/YanxunXu/doct.
The rest of the chapter is organized as follows. In section 3.2, we present the pro-
posed Bayesian joint model consisting of the decision model (for visitation schedules
and dosages) and the observation model (for clinical longitudinal measurements and
patient survival). In section 3.3, we elaborate on our optimization procedure for the
decision model. We evaluate the proposed method through simulation studies in sec-
tion 3.4 and applying it to the DIVAT kidney transplantation dataset in section 3.5.
























Figure 3.2: Illustration of the proposed method.
3.2 A Bayesian Joint Model
In this section, we describe the proposed Bayesian joint framework that models
both clinical decisions and observations. In section 3.2.1, we introduce the clinical
decision model for follow-up visitation schedules and dosages; in section 3.2.2, we
introduce the clinical observation model for longitudinal measurements and time-
to-event data, which are linked to the decision model through parameter sharing.
To facilitate our presentation and readers’ understanding, we will use the kidney
transplantation example and the DIVAT data to illustrate the model. However, the
proposed method is applicable to general medical settings since the patterns that the
method can capture are not tied to this particular application.
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3.2.1 Modeling clinical decisions
Modeling event data with marker information is important to learn the latent
mechanisms that govern the observed stochastic event patterns over time in many
domains, such as social science (Butts and Marcum, 2017) and medical analytics (Liu
et al., 2018). Marked temporal point processes (Aalen et al., 2008) are a general
framework for modeling such event data. Formally, a marked temporal point process
is a random process, the realization of which consists of a sequence of events localized
in time, i.e., H = {(t0, d0), (t1, d1), . . . , (tJ , dJ)} with the occurrence time of event j
being tj ∈ R+ and dj is the associated mark. In our application, tj represents the time
when a patient visits an outpatient center and dj represents the tacrolimus dosage
assigned by the physician. The first event is defined as the day of transplantation at
t0 = 0 with an initial dose d0.
Denote the event history up to time t to be Ht = {(tj, dj) ∈ H | tj < t}.
Under MTPP, the instantaneous rate of the event is characterized by a conditional
intensity function λ(t), namely λ(t) = limdt→0
Pr{event happens in [t,t+dt)|Ht}
dt
. Common
forms of the conditional intensity function λ(t) include Poisson process (Zhu and
Li, 2018), Gamma process (Shibue and Komaki, 2020), Hawkes process (Hawkes,
1971). However, these common models cannot capture complicated patterns in many
medical applications. For instance, as shown in Figure 3.3(a) that plots the empirical
intensity of the amount of time between visitations for different ranges of creatinine
levels in the DIVAT data, the elapsed time between follow-up visitations is correlated
with the creatinine level. Also, the empirical intensities of visitations are observed to
quickly rise to a peak and then fall down accompanied by moderate oscillations. Such
complication is beyond the capacity of the Poisson process that assumes a constant
intensity and the Gamma process whose intensity function is monotonic. The Hawkes
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process assumes that the past events always elevate the intensities of future events
and this “self-exciting” effect is additive—it is also apparently not the dynamics that
the visitations in the DIVAT data actually follow. Its neural extensions (Du et al.,
2016; Mei and Eisner, 2017) are flexible enough to fit complex data but unable to
explicitly incorporate human expert knowledge.


















(a) Empirical intensity (b) The proposed intensity
Figure 3.3: Panel (a) shows the empirical intensity plot for the amount of time
(in days) between follow-up visitations. Panel (b) plots an example of how cre-
atinine levels and model parameters affect the visitation intensity, where k = 2,
βα = (10,−1.8)T , µ = −4.4, ν1 = 1.5, and ν2 = 1.
We propose a flexible conditional intensity function that also incorporates hu-
man intuition: it takes longitudinal clinical measurements into account and captures
patients’ heterogeneity. Denote yi,j to be the longitudinal clinical measurement of
interest: in our kidney transplantation application, it is the logarithm of the creati-
nine level (µmol/l), for patient i at the j-th follow-up visitation occurring at time ti,j
(days), i = 1, . . . , I, j = 0, . . . , Ji. Note here ti,0 = 0 denotes the transplantation date
of patient i, and yi,0 denotes the initial creatinine level. Our conditional intensity
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function makes use of a Gamma density function as follows:
λi(t) = exp(µ)︸ ︷︷ ︸
Baseline Intensity




for t ∈ (ti,j, ti,j+1], (3.1)
where αi,j > 0, γ > 0, κ ≥ 1. The parameter αi,j is patient-specific so that our
intensity function λi is personalized. We set κ = exp(ν2) + 1 > 1 so that the intensity
rises to a “global peak” and then decreases: it would eventually approach to the
“baseline level” exp(µ) unless the next visitation happens and sets up a new intensity
curve. For easy interpretation, we parameterize γ as γ = exp(ν2 − ν1) such that
the “peak time” (i.e., when the peak of the intensity function occurs) can be easily
computed as κ−1
γ
= exp(ν1). Moreover, since the intensity level is often correlated
with the clinical measurement (e.g., as in Figure 3.3(a), a higher creatinine level
implies a higher intensity), we condition the parameter αi,j, which controls the peak
intensity for patient i between time ti,j and ti,j+1, on the clinical measurement taken
at the j-th visitation:
αi,j =
ξ
1 + exp((1, yi,j)βα)
.
This design reflects the human intuition that the time of “next visit” is usually deter-
mined based on the clinical measurement of “this visit.” Note that our design allows
incorporating other covariates (i.e., measurements) by simply augmenting them to
the vector (1, yi,j). Figure 3.3(b) shows how the visitation intensity under our model
is affected by the most recent creatinine level yi,j (and thus the magnitude parameter
αi,j) given a specific set of parameter values.
Next, we model the dosage di,j at the j-th visitation of patient i as the “mark” of
the visitation event: in the kidney transplantation application, it is the logarithm of
the tacrolimus level (ng/ml). Generally speaking, the physician would assign a dosage
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based on the patient’s current clinical measurement yi,j and potential risk factors xi.
We assume the following dosage model reflecting this knowledge:
di,j = (1, yi,j,xi)βd + ζi,j, (3.2)
where ζi,j ∼ Normal(0, σ2d). In the kidney transplantation application, xi includes
baseline risk factors that would affect graft failure such as the patient’s age when re-
ceiving the transplantation and the donor type. Thus, the probability of the i-th pa-
tient’s sequence of visitations and assigned dosages ei,Ti = {(ti,0, di,0), . . . , (ti,Ji , di,Ji)}
up to time Ti can be written as



















λi(ti,j | yi,j−1,βv)︸ ︷︷ ︸
Prob. of a visit at ti,j
,
(3.3)
where yi = (yi,0, . . . , yi,Ji), βv = {µ, ν1, ν2, ξ,βα}.
3.2.2 Modeling clinical observations
In this section, we introduce the clinical observation model of the Bayesian joint
framework that handles longitudinal measurements and time-to-event data. In the
kidney transplantation application, the longitudinal measurement is the creatinine
level and the time-to-event data is the graft survival time. We will also show how it is
linked to the MTPP model proposed in section 3.2.1 by carefully designing parameter
sharing in order to capture the mutual influence between clinical observations and
decisions. Shortly in section 3.3, we will leverage this joint framework to optimize
61
clinical decisions with the goal of maximizing patients’ survival.
Our clinical observation model is composed of two submodels—a linear mixed
effects model for longitudinal clinical measurements (e.g., creatinine levels) and a
time-to-event model for patient survival (e.g., graft survival time after kidney trans-
plantation). The two submodels are then connected by sharing random effects (Ri-
zopoulos et al., 2014). Recall that yi,j = yi(ti,j) denotes the longitudinal measurement
value for patient i at j-th follow-up visitation at time ti,j, i = 1, . . . , I, j = 0, . . . , Ji.




i (t) + εi,j = zi(t)βl + ri(t)bi + εi,j, (3.4)
where εi,j ∼ Normal(0, σ2l ) and bi ∼ Normal(0,Σb). The covariate vectors zi(t) and
ri(t) are associated with fixed and random effects respectively:
zi(t) = (1, di(t),xi, t, t
2) and ri(t) = (1, di(t), t),
where di(t) at time t is the dosage assigned by the physician at the most recent
visitation, i.e., di(t) = di,j for t ∈ (ti,j, ti,j+1]. The temporal dependence of z and r on
the dosage d captures the drug effect on the longitudinal measurements of interest: in
the kidney transplantation application, it is supposed to capture the suppressive effect
of tacrolimus on the creatinine level. Denote di = (di,0, . . . , di,Ji), the probability of
the observed sequence of creatinine measurements yi is
p(yi | di,xi,βl, σ2l , bi) =
Ji∏
j=1
p(yi,j | ti,j, di,j−1,xi,βl, σ2l , bi). (3.5)
Next, we construct the time-to-event submodel depending on the underlying true
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longitudinal trajectory y∗i (t) and the MTPP that models clinical decisions. We con-
sider a Weibull proportional hazards model as follows:
hi(t) = exp
(
− ( βs1y∗i (t)︸ ︷︷ ︸
longitudinal effect
+ βs2di(t) + βs3Toxi(t)︸ ︷︷ ︸
dosage effect






where ω is the shape parameter of the Weibull baseline hazard. The dependence on
y∗i (t) reflects the domain knowledge that the survival event is usually associated with
the underlying health condition reflected by longitudinal measurements. The dosage
effect term in equation (3.6) measures the overall drug effect on the patient: βs2di(t)





where the parameter ηtox controls the rate of the exponential weighting for the past
dosages. In practice, the instantaneous effect is usually beneficial (e.g., tacrolimus
reduces the likelihood of graft rejection or death) while the accumulated effect is often
toxic (and that is why we name it Tox): e.g., a prolonged high dosage of tacrolimus
might have adverse effects on kidneys, central nervous system, and gastrointestinal
tract, thereby worsening a patient’s survival (Randhawa et al., 1997). We also link the
survival submodel with the visitation model by defining αi(t) = αi,j for t ∈ (ti,j, ti,j+1]
since a high visitation intensity (i.e., larger αi,j) typically implies a higher risk, e.g.,
graft failure and thus shorter expected survival time.
Let Ti and Ci denote the survival and censoring times for patient i, respectively.
We observe only T̃i = min(Ti, Ci) and the censoring indicator δi = 1(Ti ≤ Ci).
Denote fi(t) and Si(t) to be the corresponding density and survival functions of the
hazard function (3.6): Si(t) = exp(−
∫ t
0
hi(u)du), fi(t) = hi(t)Si(t). We can write the
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survival likelihood for patient i as
p(T̃i, δi | yi,xi, ei,T̃i ,βl, bi,βs) = fi(T̃i | yi,xi, ei,T̃i ,βl, bi,βs)
δi
×Si(T̃i | yi,xi, ei,T̃i ,βl, bi,βs)
1−δi , (3.7)
where βs = {ω, βs1, βs2, βs3, βs4, h0, ηtox,βα, ξ}.
In summary, we propose a joint model consisting of an MTPP for clinical decisions
including follow-up visitation schedules and dosages, a linear mixed effects model for
longitudinal clinical measurements, and a time-to-event model for the patient survival;
they are inter-connected by sharing structures and parameters. The joint probability
of the clinical observations and decisions can then factor as
I∏
i=1













p(yi | di,xi,βl, σ2l , bi)︸ ︷︷ ︸
(3.12)





We complete the model by imposing the following priors: βd ∼ Normal(βd0,Σβd),
σ2d ∼ InverseGamma(πd1, πd2), βl ∼ Normal(βl0,Σβl), σ2l ∼ InverseGamma(πl1, πl2)
for conjugacy. We assume a flat prior for Σb. When conjugacy is unattainable for the
visitation and survival parameters, we assume βs1, βs2, βs3, βs4, h0 ∼ Normal(βs0, σ2s0),
ηtox ∼ Gamma(πs1, πs2), ω ∼ Gamma(πs3, πs4), µ, ν1, ν2 ∼ Normal(βv0, σ2v0), βα ∼
Normal(βα0,Σβα), and ξ ∼ Gamma(πv1, πv2). We carry out posterior inference using
the Markov chain Monte Carlo (MCMC) sampler. The details are included in Section
3.7.
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3.3 Optimize Personalized Clinical Deci-
sion
Our goal is to optimize personalized clinical decision including scheduling a pa-
tient’ follow-up visitations and prescribing dosages to maximize the patient’ health
outcome, e.g., the graft survival time in the kidney transplantation application. In
this section, we first formally define our optimization problem, then propose a policy
gradient method using stochastic gradient descent (SGD) (Ruder, 2016) to optimize
personalized clinical decision.
Let θ = (ν1, ν2, µ,βd, σ
2
d) denote the set of “policy” parameters related to clinical
decisions, i.e., the parameters that only appear in the conditional intensity function
(3.1) and the mark distribution (3.2), which control patients’ follow-up schedules and
dosages at follow-up visitations. Let φ = (βs, bi,βl, σ
2
l ) denote the set of “observa-
tion” parameters, i.e., all other parameters in the joint model (3.8). Our goal is to
find, for each patient i, the optimal “policy”, i.e., the intensity function and mark
distribution with the optimal parameter θ̃i that maximizes the patient’s expected
survival time. Note here we have index i for θ̃i since the optimal parameters may
be different for patients with different baseline covariates, yielding personalized opti-
mal clinical decision. We borrow the term “policy” from reinforcement learning (RL)
since the setting is similar: in RL, the “policy” refers to the distribution from which
an intelligent agent samples its actions and that distribution is optimized to achieve
the highest expected reward (Kaelbling et al., 1996; Sutton and Barto, 2018). In
the kidney transplantation application, we define a personalized reward function Ri
as the log-scaled median survival time to optimize patients’ survival: Ri = log(T̂i),
where Si(T̂i) = 0.5. If desired, other reward functions can be considered. For ex-
65
ample, if a physician or patient would like to take into consideration the healthcare
cost per visit, we could penalize the number of visitations in the reward function,
e.g., Ri = log(T̂i) + η0Ci, where η0 is a tuning parameter and Ci is the number of
visitations.
Without loss of generality, we assume that each patient i receives an arbitrary
stochastic reward that is a function of the survival time: Ri(Ti), which depends on
the MTPP ei,Ti for clinical decisions, the longitudinal process yi, and the survival
time Ti. Formally, denote the expected reward for any patient i to be
Gi(θ) =
∫
E(yi,Ti,ei,Ti )∼p(yi,Ti,ei,Ti |θ,φ)[Ri(Ti)]p(φ | D)dφ, (3.9)
where p(yi, Ti, ei,Ti | θ,φ) is the joint distribution of (yi, Ti, ei,Ti) in (3.8), D denotes
the observed data, and p(φ | D) is the posterior distribution of φ. The expectation
is taken over all possible realizations of (yi, Ti, ei,Ti). We aim to find the optimal
clinical decision, represented by θ̃i, to maximize the expected reward Gi(θ) for patient
i after integrating out the uncertainty in the longitudinal process and the survival
distribution:
maximizep(ei,Ti |θ)Gi(θ),
where p(ei,Ti | θ) is the probability density of the MTPP.
To find the optimal clinical decision parameter θ̃i for patient i, we use stochastic
gradient descent (SGD) (Robbins and Monro, 1951), i.e.,θi,m+1 = θi,m+si,m∇θGi(θ) |θ=θi,m ,
which requires computing the gradient of the expected reward: ∇θGi(θ). As the ex-
pectation is taken over realizations of the joint distribution p(yi, Ti, ei,Ti | θ,φ), it
is intractable to directly compute ∇θGi(θ). Fortunately, we can indirectly compute
this gradient by taking the expectation of the reward-weighted gradient of log-policy.
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Precisely,
Proposition 3.3.1 For the i-th patient with baseline covariates xi, given a joint




E(yi,Ti,ei,Ti )∼p(yi,Ti,ei,Ti |θ,φ)[Ri(Ti)∇θ log p(ei,Ti | yi,xi,φ,θ)]p(φ | D)dφ,
where p(ei,Ti | yi,xi,φ,θ) is the probability of the i-th patient’s sequence of visitations
and assigned dosages in (3.11).
Proof:
The expected reward function in Proposition 3.3.1 can be re-written as:



































Here we take the expectation with respect to the event history given the number of
events, and then take the expectation with respect to the number of events. Then,
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= E(yi,Ti,ei,Ti )∼p(yi,Ti,ei,Ti |θ,φ)[Ri(Ti)∇θ log p(ei,Ti | yi,xi,θ,φ)],
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where















According to Proposition 3.3.1, in order to compute ∇θGi(θ), we first need to
be able to sample yi, Ti, ei,Ti from p(yi, Ti, ei,Ti | θ,φ) and calculate Ri(Ti) from the
generated samples. We sample the j-th follow-up visitation time ti,j and the survival
time Ti using an inverse transform sampling method: first computing the cumula-
tive distribution function (CDF) of the distribution, sampling a random number U
from Uniform(0, 1), and then inverting the CDF function at U to yield the visita-
tion/survival time (Giesecke et al., 2011). If the j-th visitation time occurs before the
survival time, i.e., ti,j < Ti, we sample yi,j and di,j from their respective distributions
and continue to sample the (j + 1)-th visitation time and the survival time. We iter-
atively sample follow-up visitation times, survival times, longitudinal measurements,
and dosages until the sampled survival event occurs before the next visitation time.
After obtaining samples of yi, Ti, ei,Ti , we can easily compute Ri(Ti). We describe
the sampling process for a general Ri in Algorithm 2 and for the reward being the
log median survival time in Algorithm 3. Comparing these two algorithms reveals
computational and variance-reduction advantages of selecting the log median survival
time as the reward.
Next we compute the gradient of the log-likelihood of the MTPP, ∇θ log p(ei,Ti |
yi,xi,φ,θ), using the parametrization defined in (3.11). The details are described
in Section 3.8. Lastly, we integrate out φ in computing ∇θGi(θ) using the Monte
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Algorithm 2 Sampling yi, Ti, ei,Ti from the joint model and computing Ri(Ti)
Using the superscript s to denote the simulated data, esi,T si =
{(tsi,0, dsi,0), . . . , (tsi,Jsi , d
s
i,Jsi
)} and ysi = (ysi (tsi,1), . . . , ysi (tsi,Jsi )) denote the simu-
lated follow-up schedules, dosages, and longitudinal data over Jsi visits until the
survival time, T si .
Input: θ, φ, xi, yi,0








1: Initialize j ← 1, continue ← true
2: tsi,0 ← 0
3: ysi (0)← yi,0
4: dsi,0 ← Normal((1, ysi (0),xi)βd, σ2d)
5: while continue do
6: Uv ← Uniform(0, 1)




8: Us ← Uniform(0, 1)









i,j)← (1, dsi (tsi,j−1),xi, tsi,j, tsi,j2), rsi (tsi,j)← (1, dsi (tsi,j−1), tsi,j)
12: ysi (t
s
i,j)← Normal(zsi (tsi,j)βl + rsi (tsi,j)bi, σ2l )
13: dsi,j ← Normal((1, ysi (tsi,j),xi)βd, σ2d)
14: j ← j + 1
15: else
16: Jsi ← j − 1, continue ← false




i,0), . . . , (t
s
i,Jsi
, dsi,Jsi )} and y
s






Carlo method since it is analytically intractable. Suppose that we have K MCMC
draws from the posterior distribution of φ and we denote the k-th draw as φk, then
∇θGi(θ) can be approximated as follows:
∇θGi(θ) ≈
∑K




To compute each term of the summation in the numerator of (3.10), we first sample
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Algorithm 3 Sampling yi, ei,T̂i from the joint model and computing Ri = log(T̂i)
Using the superscript s to denote the simulated data, es
i,T̂i
=
{(tsi,0, dsi,0), . . . , (tsi,Jsi , d
s
i,Jsi
)} and ysi = (ysi (tsi,1), . . . , ysi (tsi,Jsi )) denote the simu-
lated follow-up schedules, dosages, and longitudinal data over Jsi visits until the
median survival time, T̂i. The simulated survival and hazard functions are denoted
Ssi (t) and h
s
i (t), where S
s




Input: θ, φ, xi, yi,0




1: Initialize j ← 1, continue ← true
2: tsi,0 ← 0
3: ysi (0)← yi,0
4: dsi,0 ← Normal((1, ysi (0),xi)βd, σ2d)
5: while continue do
6: Uv ← Uniform(0, 1)









9: if Ssi (t
s
i,j) > 0.5 then
10: zsi (t
s
i,j)← (1, dsi (tsi,j−1),xi, tsi,j, tsi,j2), rsi (tsi,j)← (1, dsi (tsi,j−1), tsi,j)
11: ysi (t
s
i,j)← Normal(zsi (tsi,j)βl + rsi (tsi,j)bi, σ2l )
12: dsi,j ← Normal((1, ysi (tsi,j),xi)βd, σ2d)
13: j ← j + 1
14: else
15: Jsi ← j − 1, continue ← false
16: es
i,T̂i
← {(tsi,0, dsi,0), . . . , (tsi,Jsi , d
s
i,Jsi
)} and ysi ← [ysi (tsi,1), . . . , ysi (tsi,Ji)]
17: Solve for T̂i: exp(−
∫ T̂i
0
hsi (u)du) = 0.5
18: Ri ← log(T̂i)
19: end if
20: end while
Ti, yi, and ei,Ti from p(yi, Ti, ei,Ti | θ,φk) using Algorithm 2 to compute Ri(Ti) for
each φk, then multiply the gradient of the log-probabilities of visitation times and
dosages under the MTPP policy. The entire SGD algorithm for finding the optimal
parameter θ̃i is described in Algorithm 4, where Gi(θi,m) denotes the expected reward
in iteration m. Note that, in the step 7 of Algorithm 4, we subtract the average reward
from each individual reward: this “baseline subtraction” trick significantly reduce the
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variance while still yielding an unbiased estimate of the gradient (Greensmith et al.,
2004; Williams, 1992).
Algorithm 4 Stochastic Gradient Descent for optimizing θ for patient i
Input θ0, φk (k = 1, . . . K), xi, yi,0.
Output θ̃i
1: Initialize θi,1 ← θ0
2: for m:=1 to M-1 do
3: for k:=1 to K do
4: do Algorithm 2(θi,m, φk, xi, yi,0) to sample Ri,k, e
s,k
i,T si,k














8: θi,m+1 ← θi,m + si,m∇θGi(θi,m)
9: end for
10: m∗ ← arg maxmGi(θi,m)
11: θ̃i ← θi,m∗
3.4 Simulation Study
To demonstrate the advantage of the proposed Bayesian joint model, we compared
it to an alternative model that breaks the connection between longitudinal and sur-
vival processes. Furthermore, to illustrate the benefit of optimizing the personalized
clinical decision, we compared the expected reward under the estimated optimal clin-
ical decision to alternative strategies of scheduling follow-up visitations on a regular
basis, e.g., every three months (Israni et al., 2014).
3.4.1 Simulation setup
We simulated a dataset mimicking the DIVAT dataset composed of longitudi-
nal creatinine measurements, follow-up schedules, tacrolimus dosages, and survival
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events for I = 500 patients. We considered three baseline covariates in xi: donor
age (AgeD), delayed graft function (DGF), and body mass index (BMI). DGF is
a binary variable with 1 indicating that the patient used dialysis within the first
week of the transplant, 0 otherwise. For each patient, the donor age and BMI were
generated from Normal(52.5, 15.82) and Normal(24.3, 4.52), respectively, and then
standardized. Patients’ delayed graft functions were generated from Bernoulli(0.4)
independently. In the MTPP model for follow-up schedules, the simulated true pa-
rameters were set to be ν1 = 2.5, ν2 = 1.5, µ = −4.8, ξ = 2, and βα = (9.5,−1.5)T
so that a higher creatinine level results in a higher visitation intensity; for assigning
dosages, the simulated true βd was set to be (1, 0.2, 0.15, 0.2, 0.15)
T and σd = 0.3.
In modeling log-transformed longitudinal creatinine levels, the simulated true pa-






. Note that the last two terms in the simulated
true βl were small since the times were recorded in days. Patients’ initial log-
transformed creatinine levels right after transplantation yi,0’s were independently
generated from Normal(5, 0.12). In the survival submodel (3.6), we assumed that
the simulated true parameters were h0 = 5, ω = 1.05, βs1 = 1, βα = −5, βs2 = 0.9,
βs3 = −0.75, and ηtox = 50. The censoring times Ci’s were independently generated
from Weibull(3, 8000). Based on the proposed Bayesian joint model in Section 3.2,
we generated the data yi, ei,T̃i , T̃i, δi for each patient i, i = 1, . . . , I.
The simulated dataset had a total of 14,395 follow-up visitations for 500 patients
with a 10.8% censoring rate. The median survival time was 1,684 days with the short-
est being 24 days and the longest being 10,016 days. Figure 3.4 plots the simulated













































































































































































































































































































































































































Figure 3.4: Longitudinal measurements (solid lines) and dosages (dashed lines)
over time for four randomly selected patients from the simulated dataset. The points
represent the visitation times.
3.4.2 Results: model fitting
We applied the proposed Bayesian joint model to the simulated dataset. The
hyperparameters were set to be βd0 = βl0 = βα0 = 0, Σβd = Σβl = Σβα = 100
2I,




2, πv1 = 400, πv2 = 200. We ran 20,000 MCMC iterations with
an initial burn-in of 5,000 iterations and a thinning factor of 50. The convergence
was assessed using R package coda, including traceplots of the post-burn-in MCMC
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samples for some randomly selected parameters (Figure 3.5), showing no issues of
non-convergence. We first report on the performance of the proposed joint model in
terms of parameter estimation. Figure 3.6 plots the 95% estimated credible intervals
(CIs) for selected parameters, showing that all 95% CIs are centered around the
simulated true values. As another metric of performance, we computed the mean
squared error (MSE) taken as the averaged squared errors between the post-burn-in
MCMC posterior samples and the simulated true values. Table 3.1 summarizes the
MSE and the standard deviation of squared errors, indicating that the proposed joint
model can accurately estimate parameters.
























































































Figure 3.5: Post burn-in trace plots for selected parameters in the simulation study.
βl2 is the coefficient associated with the dosage in βl and βd2 is the coefficient as-
sociated with longitudinal measurements in βd. B1,1 represents the variance in the
patient-specific random effect for longitudinal measurements. The red line represents
the parameter’s simulated truth.
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(c) Survival parameters
Figure 3.6: 95% credible intervals for parameters in the dosage, longitudinal, and
survival submodels. The dosage and longitudinal values are in log-scale. The squares
represent the simulated true values.
clinical decisions, longitudinal markers, and the survival event, there is no existing
method we can compare with. To demonstrate the advantage of jointly modeling
longitudinal creatinine levels and the survival event, we compared the proposed model
with an alternative “separate longitudinal and survival (SIS)” model that breaks the
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Truth MSE SD of squared errors
βs1 1 0.0192 0.0220
βs2 0.9 0.256 0.348
βs3 -0.75 0.168 0.2194
βs4 -5 0.0688 0.0922
h0 5 0.678 0.704
ω 1.05 1.34× 10−3 1.57× 10−3
σ2l 0.01 6.31× 10−8 6.25× 10−8
σ2d 0.09 1.69× 10−5 9.34× 10−6
µ -4.8 5.12× 10−4 4.99× 10−4
ξ 2 8.99× 10−3 1.32× 10−2
ν1 2.5 2.49× 10−4 3.11× 10−4
ν2 1.5 3.01× 10−3 3.64× 10−3
Table 3.1: MSE and standard deviation of squared errors for randomly selected
parameters in the simulation study.
connection between the longitudinal and survival submodels by replacing the process
y∗i (t) with the observational data yi(t) in the hazard model (3.6). We first compared
the two models by checking their model adequacy using widely applicable information
criterion (WAIC) (Gelman et al., 2014): the joint model has a WAIC value of 226,982
while theSLS model has a WAIC of 226,992, indicating that the proposed joint model
fits data slightly better. Furthermore, we compared the two models in terms of
parameter estimation. Table 3.2 reports the simulated true values of parameters in
the survival submodel, and posterior means of these parameters under the joint model
and the SLS model with 95% CIs, showing that the joint model estimates parameters
more accurately.
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Truth Joint posterior mean (95% CI) SLS posterior mean (95% CI)
βs1 1 1.1(0.92,1.26) 1.19(0.94,1.6)
βs2 0.9 1.25(0.74,1.95) 1.41(0.63,2.3)
βs3 -0.75 -0.92(-1.62,-0.33) -1.03(-1.8,-0.18)
βα -5 -5.01(-5.51,-4.47) -5.16(-6.14,-4.56)
h0 5 4.36(3.44,5.35) 3.89(1.6,5.22)
ω 1.05 1.06(0.99,1.12) 1.06(0.97,1.13)
Table 3.2: Parameter estimation under the joint and SLS models.
3.4.3 Results: personalized optimal clinical deci-
sion estimation
We applied the proposed policy gradient method in Section 3.3 to the simulated
dataset to estimate the personalized optimal clinical decision that maximizes one
patient’s graft median survival time, i.e., Ri = log(T̂i), where T̂i is the median survival
time of patient i. The starting parameter values θ0 in Algorithm 4 were set to be the
estimated posterior means of these parameters from posterior inference, which can be
considered as the estimates of how physicians treated patients in the simulated data.
Therefore, the goal of the optimization procedure is to improve physicians’ current
treatment strategy in terms of prolonging patients’ survival.
We implemented Algorithm 4 with M = 1000 steps to estimate the personalized
optimal parameter θ̃i for two randomly selected patients, denoted as S1 and S2.
Patient S1 had a DGF of 0, donor age of 54.2 years, and BMI of 24, while patient
S2 had a DGF of 1, donor age of 37.4 years, and BMI of 24.8. Figure 3.7(a, b)
plots the expected mean reward versus SGD iterations. For patient S1, the expected
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mean reward increases from an initial value of 7.65 to its maximum in the SGD, 7.69,
which corresponds to a predictive median survival time of 2,209 days, a 4.6% increase
from its initial value 2,111. For patient S2, the expected mean reward goes from an
initial value of 7.69 to a maximum at 7.76. This corresponds to the predictive median
survival time increasing from 2,203 days to 2,383 days, an 8.2% improvement.
To further interpret the estimated optimal “policy” parameters for patients S1
and S2, we compared the initial parameter values of the SGD–posterior means, with
the optimized values by the SGD in Table 3.3. Recall that the dosage model is di,j =
(1, yi,j,xi)βd + ζi,j. Denote βd = (βd1, βd2, . . . , βdL)
T , where L is the dimension of βd.
Since xi denotes the baseline covariate and does not change over time, we define the
personalized dosage intercept to be β̃d = (1,xi)(βd1, βd3, . . . , βdL)
T so that optimizing
βd is equivalent to optimizing (βd2, β̃d). As shown in Table 3.3, the optimized dosage
parameters β̃d and βd2 for patient S1 were lower than the estimated posterior means,
indicating that patient S1 would benefit from a lower dosage for the same creatinine
level compared to the observed dosages. In contrast, the optimal β̃d and βd2 were
higher than the posterior means for patient S2, indicating the preference for higher
dosages. The optimal dosage errors, σ2d, for both patients were significantly lower
than the initial value, indicating that a lower variance in the dosing procedure would
benefit patient survival. The optimal baseline visitation intensity µ and the peak
time parameter ν1 were both roughly the same as their posterior means, indicating
that the simulated follow-up schedules were close to optimal. However, the visitation
intensity shape parameter ν2 increased from 1.464 to 1.778 and 2.008 for patients
S1 and S2 respectively and thus implies a higher intensity around the peak time ν1:
intuitively, the optimized policy learns to be more certain about the “optimal peak
time.”
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(c) Patient S1 (d) Patient S2
Figure 3.7: Panels (a, b) plot the expected mean reward versus SGD iterations
for two randomly selected patients S1 and S2. Panels (c, d) plot the density of the
predictive median survival times under our method and the three alternative strategies
for patients S1 and S2.
In addition, to illustrate the advantage of optimizing both follow-up schedules
and dosages, we compared our results to alternative strategies based on regular vis-
its. As studied in Israni et al. (2014), during the first year post-transplant, patients
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Table 3.3: Simulation: Stochastic Gradient Descent Optimal Parameter Results
θ̃0 θ̃S1 θ̃S2
β̃d: personalized dosage intercept S1: 0.864, S2:0.987 0.746 1.316
βd2: dosage effect of creatinine 0.200 0.153 0.307
σ2d: dosage error 0.0940 0.0217 0.00252
µ: baseline visitation intensity -4.781 -4.821 -4.785
ν1: visitation intensity peak 2.512 2.416 2.519
ν2: visitation intensity shape 1.464 1.778 2.008
were most frequently seen every 1 month or 3 months, depending on their physicians.
After the first year, stable patients were most frequently referred back between 4-6
months but the follow-up frequency was reported to vary from 0-12 months. We
considered three alternative follow-up strategies: recommend patients to follow up
every 1 month, 3 months, and 6 months. The dosages at follow-up visitations were
still optimized in the same way as the proposed joint model with the policy gradient
method. Figure 3.7(c, d) show the density plots of 100 realizations of the predictive
median survival times under our method and the three alternative strategies for pa-
tients S1 and S2. Comparing the predictive median survival times under the three
regular visitation strategies, we can see that more frequent visitations yield longer me-
dian survival times. The optimized visitation schedule under the proposed method
outperforms the three alternative strategies although it yields a similar overall vis-
itation frequency with the strategy of “regular visits every 3 months” (not shown),
highlighting the importance of optimizing visitation schedules based on longitudinal
clinical measurements to prolong patients’ survival.
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3.5 Application: DIVAT Data Analysis
We extracted data from Nantes University Hospital Centers in the DIVAT cohort
(www.divat.fr), yielding a total of N = 947 patients who received a first or sec-
ond renal graft transplanted from a living or heart-beating deceased donor between
2000 and 2014. All patients in the dataset received an initial maintenance therapy
with tacrolimus and did not experience graft failure or death during hospitalization.
Immediately after transplantation, several baseline covariates as risk factors for graft
failure were collected: donor age (AgeD), recipient age (AgeR), delayed graft function
(DGF) defined as the indicator of the use of dialysis within the first week of transplant
(1=used dialysis, 0=didn’t use dialysis), diabetes history (Diab) with 1 indicating the
patient has a history of diabetes and 0 otherwise, type of donor (Type), and body
mass index (BMI). There were two types of donors: donation after brain death but
with heart beating (Type=1) and donation by a living donor (Type=0). Table 3.4
summarizes patients’ characteristics at baseline immediately after transplantation.
For each patient, longitudinal data were collected from the date of transplantation
until the graft failure or being censored. At each follow-up visitation, the creatinine
level and tacrolimus dosage were recorded. The next follow-up visitation time was
determined by the physician.
3.5.1 Experimental results: model fitting
We first applied the proposed Bayesian joint model to the DIVAT data with
xi = (AgeDi,AgeRi,DGFi,BMIi,Diabi,Typei). The hyperparameters were set to
the same as in the simulation study. We ran a total of 20,000 MCMC iterations with
an initial burn-in of 5,000 iterations, and a thinning factor of 50. The convergence was
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Donor age (years)
Mean ± SD 52.5 ± 15.8
Median 54
Receipient age (years)
Mean ± SD 51.1 ± 14.3
Median 52
Body mass index (BMI)
Mean ± SD 24.3 ± 4.5
Median 23.7






Type of donor, n(%)
Yes 800 (84.5%)
No 147 (15.5%)
Table 3.4: Patient characteristics at baseline immediately after transplantation.
assessed using R package coda and the trace plots for randomly selected parameters
were shown in Figure 3.8, showing no issues of non-convergence.
We plot the estimated posterior means with 95% CIs for some selected parameters
in the dosage, longitudinal, and survival submodels in Figure 3.9. Figure 3.9(a) plots
posterior means of the linear coefficient βd with respect to the creatinine level and
baseline covariates in the dosage model. DGF was negatively associated with the
dosage, indicating that patients who used dialysis within the first week of transplant
were likely to be assigned lower dosage levels. In contrast, BMI was positively associ-
ated with the dosage since bodyweight-based dosing of tacrolimus is the standard care
for patients after transplantation (Andrews et al., 2017). Diabetes history was posi-
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Figure 3.8: Post burn-in trace plots for randomly selected parameters in the DI-
VAT data analysis. βl2 is the coefficient associated with the dosage in βl and βd2 is
the coefficient associated with longitudinal measurements in βd. B1,1 represents the
variance in the patient-specific random effect for longitudinal measurements.
tively associated with the dosage. While the effect of diabetes on tacrolimus was not
well characterized in the literature, Mendonza et al. (2007) showed that the time to
maximum concentration of tacrolimus in the pharmacokinetics study was significantly
longer in diabetics versus nondiabetics. Furthermore, donor type also increased the
dosage level, indicating that patients who received kidney from a non-living donor
were more likely to be assigned higher dosages compared to that from a living donor.
Figure 3.9(b) plots the estimated posterior means with 95% CIs for the fixed-effects
regression coefficients with respect to the most recent tacrolimus dosage and baseline
covariates in the longitudinal model (3.4). The dosage, donor age, DGF, BMI, and
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(c) Survival parameters
Figure 3.9: Estimated posterior means and 95% CIs for parameters in the dosage,
longitudinal, and survival submodels. The dosages and longitudinal measurements
are in log-scale. The squares represent posterior means.
findings in the literature (Foucher et al., 2016; Gerchman et al., 2009; Katari et al.,
1997). In contrast, the recipient age was negatively associated with the creatinine
level, suggesting that younger patients tend to have lower creatinine levels (Maraghi
et al., 2016). Diabetes history also decreased the creatinine level. Hjelmeseth et al.
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(2010) showed that a low creatinine was associated with type 2 diabetes in a cross-
sectional study. The estimated posterior means and 95% CIs for selected survival
submodel parameters are plotted in Figure 3.9(c). The posterior mean of the param-
eter corresponding to the tacrolimus dosage was positive while that corresponding
to the toxicity was negative, suggesting that a higher tacrolimus drug reduces the
hazard but the accumulated toxicity increases the hazard. These results were consis-
tent with findings in Randhawa et al. (1997) and Böttiger et al. (1999), who reported
nephrotoxicity caused by long-term high dosages of tacrolimus.
3.5.2 Experimental results: personalized optimal
clinical decision estimation
Next, we applied the proposed policy gradient method to estimate the personalized
optimal clinical decision in terms of maximizing a patient’s median survival time.
We initialized the parameters in Algorithm 4 by setting θ0 to be their posterior
means. Algorithm 4 was implemented with M = 1000 steps to estimate θ̃i for two
randomly selected patients, denoted as R1 and R2. Patient R1 at transplantation
was 60 years old with a BMI of 17, no history of diabetes, no DGF, and received
donation from a 61-year-old non-living donor. Patient R2 at transplantation was
28 years old with a BMI of 25.5, no history of diabetes, no DGF, and received a
kidney from a living 29-year-old donor. Patient R1 had an observed survival time of
1,527 days, while patient R2 had a censored survival time of 4,487 days. Figure 3.10
plots the predictive median survival times across SGD iterations for the two patients.
Patient R1’s predictive median survival time increased from 1,793 to 1,895 days at
the maximum, a 5.7% improvement; while patient R2’s predictive median survival
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time increased from 5,191 to 5,628, an 8.4% gain.






















































(a) Patient R1 (b) Patient R2
Figure 3.10: The expected mean reward versus SGD iterations for two randomly
selected patients R1 and R2.
To further interpret the estimated optimal parameters in clinical decisions, we
compared their initial values with the optimized values in Table 3.5. Patient R1’s
optimal dosage parameters, β̃d and βd2, were higher than their posterior means, sug-
gesting that assgining a higher dosage level compared to what the physician actually
did for the same creatinine level would improve his/her survival outcome. On the
other hand, patient R2’s optimal dosage parameters were both lower than the initial
values, so lower dosage levels are recommended. The optimal dosage errors, σ2d, for
both patients were significantly lower than the initial value, meaning that the opti-
mized policy is more certain about its dosing decisions so the variance is lower than
the observed data. The optimal baseline visitation intensities µ for both patients
were lower than the initial value, indicating that they should be instructed to visit
less often without the knowledge of their creatinine measurements. Their optimized
visitation intensity peak times were lower than the posterior mean, indicating that
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they should be scheduled more frequent follow-ups when their creatinine levels are
high. Furthermore, the visitation intensity shapes were significantly higher than the
initial value so the optimized policy is more certain about the optimal peak time for
visitation schedules.
Table 3.5: DIVAT data: optimal parameters estimated by the policy-optimizing
method.
θ̃0 θ̃R1 θ̃R2
β̃d: personalized dosage intercept R1:2.367, R2:2.363 2.788 2.161
βd2: dosage effect of creatinine -0.038 0.076 -0.065
σ2d: dosage error 0.111 0.035 0.0024
µ: baseline visitation intensity -4.197 -4.617 -4.322
ν1: visitation intensity peak 1.479 1.123 1.311
ν2: visitation intensity shape 0.258 0.864 1.261
3.5.3 Ablation study: optimizing time or dosage
or both
Moreover, to demonstrate the benefit of optimizing the follow-up visitation sched-
ules and dosages together, we compared the predictive median survival times under
the non-optimized initial policy (Non-Opt.) with three versions of optimized poli-
cies: 1) only visitation schedules are optimized (Opt. Visits); 2) only dosages are
optimized (Opt. Dosage); and 3) both visitation schedules and dosages are opti-
mized (Opt. Both). Specifically, Non-Opt. used the parameters estimated from the
proposed Bayesian joint model, mimicking what physicians did as collected in the
DIVAT dataset; Opt. Visits used the optimized parameters from the SGD in the
visitation model (3.1) and the non-optimized parameters in the dosage model (3.2);
Opt. Dosage used the optimized parameters from the SGD in the dosage model and
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the non-optimized parameters in the visitation model; Opt. Both is the fully opti-
mized model obtained in section 3.5.2 which used the optimized parameters in both
the visitation and dosage models. Figure 3.11 plots boxplots for 100 realizations of
the predictive median survival times under each of the four policies. The visitation
schedule optimization accounts for more improvement in prolonging the survival for
patient R1 compared to patient R2 because, as shown in Table 3.5, there was a larger
difference between the optimal parameter values (µ and ν1) in the visitation model
and their initial values for patient R1. The optimized visitation schedule for both
patients, as we have discussed in section 3.5.2, suggested slightly fewer visits over-
all, but more frequent visits when their creatinine levels are high. Comparing Opt.
Visits vs. Non-Opt. and Opt. Both vs. Opt. Dosage, we can see that optimizing treat-
ment schedules is clearly beneficial to these patients, thus empirically strengthening
the motivation of our work. In summary, this analysis reveals that optimizing both
visitation schedules and dosages is necessary to maximize patients’ survival.
























































(a) Patient R1 (b) Patient R2
Figure 3.11: The boxplots of the predictive median survival times under different
policies of visitation schedules and dosages for patients R1 and R2.
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3.6 Conclusion
In this work, we developed a Bayesian method that jointly models the clinical ob-
servations (e.g, longitudinal measurements and survival time) and clinical decisions
(e.g., follow-up visitation schedules and dosage assignments). The model components
are connected by sharing certain structures and parameters in order to capture the
mutual influence between the clinical observations and decisions. Moreover, we pro-
posed a policy gradient method that optimized the personalized clinical decision for
better survival, while parameter uncertainties in the clinical observation model are
considered in the Bayesian framework. Through simulation studies, we demonstrated
that the optimized clinical decision obtained from the proposed approach yields longer
predictive median survival times compared to scheduling follow-up visitations on a
regular basis that is commonly used in caring for patients with chronic conditions
nowadays. The analysis of the DIVAT data yields meaningful and interpretable re-
sults, showing that the proposed method has the potential to assist physicians’ de-
cisions on personalized treatment. In addition, we have built an R package doct so
that users can apply the proposed method to datasets in a similar setup that involves
longitudinal decision making and an objective reward to optimize.
There are several potential extensions. Firstly, we consider one longitudinal mea-
surement in the longitudinal process of the joint model. There could be other time-
varying measurements affecting the clinical decision and survival. In our kidney trans-
plantation application, besides creatinine levels, there are other longitudinal measure-
ments recorded such as proteinuria, which represents having protein in the urine and
can be an early sign of kidney disease. The proposed method can be extended to
incorporate other longitudinal measurements by replacing the model in (3.4) with a
multivariate mixed effects model (Chi and Ibrahim, 2006). Secondly, patients may be
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heterogeneous, meaning that patients in different subgroups may respond differently
to the treatment or have different disease progression and survival patterns depending
on their clinical characteristics. We can extend the proposed Bayesian joint model to
account for patients’ heterogeneity by adding index i to all parameters in (3.8) and
considering a Bayesian nonparametric prior, such as the Dirichlet process (Ferguson,
1973). Lastly, patients with chronic conditions may take multiple medicines, e.g., my-
cophenolate mofetil (an immunosuppressive drug) and steroids along with tacrolimus
in our kidney transplantation application. Modeling the effects of multiple types of
drugs (and their interactions with clinical observations) and learning their optimal
dosage-assigning policies in the proposed optimization method will be an interesting
and challenging research topic.
3.7 MCMC Sampling Details
3.7.1 Joint Model Summary
Below we first summarize the proposed Bayesian joint model before presenting the

















p(yi | di,xi,βl, σ2l , bi)︸ ︷︷ ︸
(3.12)
























λi(ti,j | yi,j−1,βv)︸ ︷︷ ︸
Prob. of a visit at ti,j
,
(3.11)
where yi = (yi,0, . . . , yi,Ji), βv = {µ, ν1, ν2, ξ,βα}.
p(yi | di,xi,βl, σ2l , bi) =
Ji∏
j=1
p(yi,j | ti,j, di,j−1,xi,βl, σ2l , bi). (3.12)
p(T̃i, δi | yi,xi, ei,T̃i ,βl, bi,βs) = fi(T̃i | yi,xi, ei,T̃i ,βl, bi,βs)
δi
×Si(T̃i | yi,xi, ei,T̃i ,βl, bi,βs)
1−δi , (3.13)
where βs = {ω, βs1, βs2, βs3, βs4, h0, ηtox,βα, ξ}.
3.7.2 MCMC Sampling Steps





p(T̃i, δi | yi,xi, ei,T̃i ,βl, bi,βs)
Ji∏
j=1






























. Note that this proposal distri-
bution is the posterior of βl if we were to ignore the survival submodel. The
Metropolis-Hastings acceptance rate is:





i=1 p(T̃i, δi | yi,xi, ei,T̃i ,β
∗
l , bi,βs)∏I
i=1 p(T̃i, δi | yi,xi, ei,T̃i ,βl, bi,βs)
.





p(T̃i, δi | yi,xi, ei,T̃i ,βl, bi,βs)
Ji∏
j=1
p(yi,j | di,j−1,xi,βl, σ2l , bi)
)
.



























. Note that this proposal distri-
bution is the posterior of bi if we were to ignore the survival submodel. The
Metropolis-Hastings acceptance rate is:




p(T̃i, δi | yi,xi, ei,T̃i ,βl, b
∗
i ,βs)
p(T̃i, δi | yi,xi, ei,T̃i ,βl, bi,βs)
).
3. Update σ2l : The prior for σ
2
l is InverseGamma(πl1, πl2), so we have
p(σ2l |·) ∝ p(σ2l )
I∏
i=1
























5. Update β∗s ∈ {βs1, βs2, βs3, βs4, h0}: since their posterior distributions are not in
closed-form, these parameters are updated using the Metropolis-Hastings. The
prior for β∗s is Normal(βs0, σ
2
s0), so we have
p(β∗s |·) ∝ p(β∗s )
I∏
i=1
p(T̃i, δi | yi,xi, ei,T̃i ,βl, bi,βs).
6. Update ηtox: We use the Metropolis-Hastings to update ηtox. The prior for ηtox
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p(T̃i, δi | yi,xi, ei,T̃i ,βl, bi,βs).
7. Update ω: We use the Metropolis-Hastings to update ω. The prior for ω is




p(T̃i, δi | yi,xi, ei,T̃i ,βl, bi,βs).
8. Update β∗v ∈ {µ, ν1, ν2}: We use the Metropolis-Hastings algorithm. The prior
for β∗v is Normal(βv0, σ
2
v0).
p(β∗v |·) ∝ p(β∗v)
I∏
i=1
p(ei,Ti | yi,xi,βv,βd, σ2d).







p(ei,Ti | yi,xi,βv,βd, σ2d)p(T̃i, δi | yi,xi, ei,T̃i ,βl, bi,βs).







p(ei,Ti | yi,xi,βv,βd, σ2d)p(T̃i, δi | yi,xi, ei,T̃i ,βl, bi,βs).
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12. Update σ2d: The prior for σ
2





















3.8 Gradient Computation Details
To calculate ∇θ log p(ei,Ti | yi,xi,θ,φ), we compute the gradient with respect to




























Let βd,l and ai,j,l refer to the l-th dimension of βd and ai,j = (1, yi,j,xi). Also,
let βd,−l and ai,j,−l refer to the other dimensions, excluding the l-th dimension
of βd and ai,j. Then, we have






































































































































(exp(ν2)(ν2 − log(exp(ν1))) + exp(ν2) + 1)(t− ti,j)exp(ν2)e− exp(ν2)(t−ti,j)/ exp(ν1)
+ eν2−exp(ν2)(t−ti,j)/ exp(ν1) log(t− ti,j)(t− ti,j)exp(ν2)




















































































A Bayesian semiparametric model
for learning biomarker trajectories
and change points in Alzheimer’s
disease
4.1 Introduction
For many diseases, the manifestation of symptoms can be difficult to identify
due to its slow development. As a result, many subjects that receive a diagnosis
for these gradually developing diseases have already been experiencing its negative
consequences for a substantial time. These detrimental effects can be subtly observed
through longitudinal biomarker data that tracks the subject’s well-being over time.
In contrast to these ”susceptible” or ”uncured” subjects, others may never develop
symptoms nor receive a diagnosis, and we typically refer to such subjects as being
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”immune” or ”cured”.
In this work, we propose a Bayesian framework that addresses several key biomed-
ical questions in such settings. First, we want to understand how the longitudinal
biomarker patterns vary based on subject baseline characteristics and inherent dis-
ease cure status in order to compute the personalized probability of an inherent cure.
For the uncured subjects, we are interested in how the diagnosis time depends on
baseline characteristics and whether we can identify a change point in the evolution
of the biomarker before diagnosis.
There is substantial literature on change point modeling for early detection of
slowly progressing diseases. Hall et al. (2000) introduces a parametric change point
model that detects when the rate of cognitive decline accelerates in people who even-
tually are diagnosed with dementia. Tang et al. (2017) further develops a two-phase
joint longitudinal and survival model where the change point is measured relative
to the survival event of manifestation of Alzheimer’s disease (AD). Within the con-
text of Alzheimer’s disease, we will refer to the susceptible/uncured subjects as non-
progressors and the immune/cured subjects as progressors to reflect whether or not
subjects will eventually progress to developing AD. Although these models are able to
robustly detect change points, they do not account for the possibility of disease non-
progression. Addressing this possibility is difficult because non-progression cannot
be directly observed and we cannot determine non-progression using only baseline
characteristics. However, we can narrow down the subjects eligible for being con-
sidered non-progressors to subjects with right-censored diagnosis times, where the
study ends before diagnosis. By hypothesizing that the progression patterns of the
biomarker vary depending on whether subjects will eventually be diagnosed, we can
make use of the longitudinal biomarker data to help determine inherent cure status
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among the censored subjects.
Embedding a binary cure submodel, which assumes some subjects will never ex-
perience the survival event, into a joint longitudinal survival framework allows us to
group subjects by whether they are non-progressors or progressors. Yu et al. (2004)
developed a joint longitudinal-survival-cure model for the prostate cancer, where the
survival event was clinical recurrence and the cured fraction is modeled as a logistic
function of baseline covariates.
In this work, we develop a flexible semiparametric Bayesian framework that jointly
models longitudinal biomarkers, individual cure status, and the disease diagnosis
time by inferring the change point for AD progression before diagnosis. We apply
our framework to an Alzheimer’s disease context, a prime example of a disease with
slowly developing symptoms. Many subjects who are diagnosed with AD are already
cognitively impaired but these detrimental effects are only observable through cer-
tain longitudinal biomarkers that are difficult to track due to cost and invasiveness.
Our data is collected through the BIOCARD study, which tracks cognitive related
biomarkers for subjects that began as cognitively normal.
4.2 Bayesian Joint Model
In this section, we describe our proposed semiparametric Bayesian framework that
jointly models longitudinal biomarker observations with a change point, diagnosis
event times, and cure status. Section 4.2.1 introduces the cure fraction model for
disease progressor/non-progressor status, section 4.2.2 introduces the time-to-event
model for diagnosis times, and section 4.2.3 introduces the longitudinal model for
biomarker measurements conditional on latent variables. Section 4.2.4 discusses the
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nonparametric Dirichlet Process Mixture model that allows subjects to share certain
structures and parameters within clusters.
4.2.1 Cure Fraction Incidence Model
Cure models are applied in survival analysis when event time data comes from a
mixed population composed of two groups: subjects who will eventually progress and
others who will never progress to the event of interest (Sy and Taylor, 2000). The
primary clinical event of interest in our context is the diagnosis event time, but the
survival event of subject death is also relevant as a censoring mechanism. For subject
i (i = 1, . . . , I), let Ui denote the diagnosis event time, Ci denote the administrative
censoring time, and Di denote the survival event time. We assume that these three
values are independent, and define the survival event time as Ti = min(Ci, Di) and
ci = I(Di≤Ci) to be the survival censoring indicator. If we denote censoring for the
diagnosis event as δi = I(Ui≤Ti), then Ui is observable only when δi = 1.
We define the cure indicator, si, such that si = 1 if subject i is a progressor, and
si = 0 if the subject is a non-progressor and diagnosis time Ui =∞. Then, there are
three possible diagnosis time censoring/cure scenarios for each subject:
1. si = 1, δi = 1 (Ui ≤ Ti)
2. si = 1, δi = 0 (Ti < Ui <∞)
3. si = 0, δi = 0 (Ui =∞)
Only subjects with a censored diagnosis event time are considered for being a non-




cXi,0 + ζi , ζi ∼ N (0, 1),
104
where Xi,0 is a vector of baseline covariates that are observed when the subject
initially enters the study at age ti,0. Then the cure status, si, is modeled as an
indicator for whether s∗i is positive:
si =

1 s∗i > 0
0 otherwisex
.
With this cure submodel, the probability of being a disease progressor can be di-
rectly computed as P (si = 1 | Xi,0,βc) = Φ(βTcXi,0), where Φ is the cumulative
distribution function of the standard normal distribution.
4.2.2 Time-to-Event Model
For progressors, we denote the distribution of the diagnosis event times, Ui, as
f(Ui | ·) and assume a linear model:
Ui |Xi,0 = βTuiXi,0 + εi,u , εi,u ∼ N (0, σ2ui)
If a progressor has a censored diagnosis event (si = 1, δi = 0), then the unobserved
Ui can be imputed from f(Ui | ·)I(Ui≥Ti). In contrast, if subject i belongs to the
non-progressor group we assume a point mass of Ui =∞. Thus, the two cure status
possibilities lead to two models for Ui with different dimensions. To resolve this
change in dimension that complicated posterior simulations, we use the pseudo prior
approach described in Carlin and Chib (1995). This approach involves defining a
prior π(U) for subjects in the non-progressor group to match model dimensions and
simplify MCMC updates. The pseudo prior is chosen by matching first and second
moments with the marginal posterior of U under a model without cure, where si = 1
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for all subjects.
4.2.3 Conditional Longitudinal Model
Denote Yi,j, Xi,j, and Zi,j to be the longitudinal biomarker measurements, fixed
effects covariates, and random effects covariates, respectively, for subject i at the
j-th observation at time ti,j (subject age in years), i = 1, . . . , I, j = 1, . . . , Ji. Our
longitudinal model for each subject is a linear mixed effects model conditional on
cure status and cluster membership for progressors. For the non-progressor group,
we assume:
Yi,j | si = 0,Xi,j,Zi,j = βT1Xi,j + bT1iZi,j + εi,j,
where εi,j ∼ N (0, σ21) and b1i∼ N (0,Σ1). On the other hand, the longitudinal
biomarker data for the progressor group is modeled by a separate linear mixed effects
model to avoid identifiability issues in the cure model:
Yi,j | si = 1,Xi,j,Zi,j, Ui = βT2iXi,j + bT2iZi,j + γi(ti,j − Ui + τi)+ + εi,j,
where εi,j ∼ N (0, σ22) , b2i∼ N (0,Σ2), and (ti,j − Ui + τh)+ = max(0, ti,j − Ui +
τh). Under this model, the longitudinal biomarkers and time to diagnosis event data
depend on each other for progressors: the change point for disease progression allows
the biomarker trend to change at a latent point τh years before the diagnosis event.
We impose a uniform prior on τh to restrict it to a clinically reasonable range.
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4.2.4 Dirichlet Process Mixture Model
In section 2.3, we introduced the Dirichlet Process prior and a nonparametric
Dirichlet Process mixture (DPM) model for survival event times. For our current
framework, we assume a DPM model for selected components of our model to clus-
ter subjects and account for subject heterogeneity. The model parameters that are
shared among clusters include the diagnosis event parameters and linear fixed effects
coefficients and change point parameters for progressors: θi = {βui, σ2ui,β2i, γi, τi}.
The DPM model can be summarized as:
Yi,j, Ui | θi ∼ F (θi)
θi | G ∼ G
G ∼ DP (G0, α),
where G is the mixing distribution for θ, G0 represents the base distribution, and
α refers to the concentration parameter. We can also represent our model using






Yi,j | si = 1,Xi,j,Zi,j, Ui ∼
∞∑
h=1




(1− vk) , vh∼Beta(1, α),
where h represents cluster membership. We implement a finite DPM model by setting
an upper bound for the total number of clusters to a finite number H. This DPM
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model allows us to account for heterogeneity among subjects by clustering them using
their diagnosis times and longitudinal measurements.
4.2.5 Joint Likelihood of the Model
In summary, we propose a joint model consisting of a cure model for individual
disease progressor status, time to event model for disease diagnosis time, a condi-
tional longitudinal model that assumes different biomarker evolution patterns based
on subject-specific latent cure status, and a DPM model that clusters subjects based
on their longitudinal and diagnosis event processes. In our context, subjects are not
enrolled if they have been diagnosed with the disease or have died before the ini-
tial recruitment time. Therefore we must modify the likelihood to account for bias




p(si = 0 | βc,Xi,0)
( Ji∏
j=1













p(Yi,j | si = 1,β2h, b2i, σ22, γh, τh,Xi,j,Zi,j, Ui = u)
)1−δi
×
p(si = 1 | βc,Xi,0)
)si
× 1




p(min(Ui, Di) ≥ ti,0 | ·) = p(Ui ≥ ti,0 | ·)× p(Di ≥ ti,0)
=
[




To compute this bias adjustment in the likelihood, we can model the death time
using a normal model: Di ∼ N (µd, σ2d). However, the modeling of death times is
not necessary for posterior inference because we can treat p(Di ≥ ti,0) as a con-
stant. We complete the model by imposing the following priors: βc ∼ N (mc,Vc),
σ2uh∼InvGamma(a0, b0), βuh∼N (mu,Vu), β1∼N (m1,V1), Σ1 ∼ InvWishart(S−11 , η1),
σ21 ∼ InvGamma(a1, b1), β2h ∼ N (m2,V2), γh ∼ N (mγ, σ2γ), τh ∼ Uniform(aτ , bτ ),
Σ2 ∼ InvWishart(S−12 , η2), σ22 ∼ InvGamma(a2, b2). We carry out posterior inference
using the Markov chain Monte Carlo (MCMC) sampler. The details are included in
Section 4.6.
4.3 Simulation Study
To evaluate our model’s ability to identify clusters of similar subjects and individ-
ual cure status while being able to accurately model the underlying event time and
longitudinal processes, we develop a simulated dataset and fit our model.
4.3.1 Simulation Setup
We simulated a dataset mimicking the AD dataset composed of longitudinal mea-
surements, diagnosis events, and survival events for 552 subjects. 52 subjects are left
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truncated (9.4% truncation rate) because their diagnosis or survival event occurred
before the first longitudinal measurement time, leaving us with I = 500 subjects.
We considered four covariates in Xi,j: an intercept, years of education (standard-
ized), sex, and time (age of subject in years). The baseline covariates, Xi,0, and
random effects covariates, Zi,j, are composed of an intercept, education, and gen-
der. For each subject, the years of education was generated from N (17, 2.4) and
sex (female=1) was sampled from a Bernoulli(0.5). Initial age was generated from
N (59, 72) and time (years) between longitudinal measurements was generated from
Exponential(1). Survival time was sampled from a Lognormal(4.4, 0.07) and 438 sub-
jects have an observed survival event.
In the cure incidence model, βc was set to (0.9, 0.3,−0.3), which results in 377
out of 500 subjects identified as progressors. Out of these, 226 subjects have an
observed diagnosis event (40% censoring rate). The progressors were generated from
two clusters, with equal probability of being in either cluster: 182 subjects are in the
first cluster, and 195 are in the second cluster. The diagnosis time model parameters






The median diagnosis time was 70 years, with the earliest diagnosis event occurring
at 52.1 years and the latest at 85.4 years.
For the longitudinal model, the parameters were β1 = (−16, 0.15, 0.8, 1), β21 =






, and σ21 = 0.22, σ22 = 0.32. The simulated dataset had a
total of 8236 longitudinal measurements.
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4.3.2 Results: model fitting and posterior infer-
ence
We applied the proposed Bayesian joint model to the simulated dataset. The
hyperparameters were set to be α = 1, mc = mu = m1 = m2 = 0, Vc = Vu = V1 =
V2 = 100
2I, S1 = S2 = 1000
2I, η1 = η2 = 4, a0 = b0 = a1 = b1 = a2 = b2 = 0.01,
mγ = 0, σ
2
γ = 1
2, aτ = 0, and bτ = 25. The model fitting process under our framework
begins with establishing a pseudo prior for the diagnosis event times. We follow the
recommendations of (Carlin and Chib, 1995) and (Zhang et al., 2010) for constructing
the pseudo prior for U , π(U), using preliminary data analysis under a model without
cure, where all subjects have si = 1. Under this simplified model with no dimensional
change, we ran 10,000 MCMC iterations with an initial burn-in of 5,000 iterations,
and a thinning factor of 10, using a finite DPM with five total clusters. Then, we
assume a normal distribution for π(U) and match the first two moments of this pseudo
prior to the marginal posterior density of U.
After the initial pseudo prior specification, the we fit the data under our proposed
model with five total clusters and 10,000 MCMC iterations with a burn-in of 5000
iterations and a thinning factor of 10. Although it’s common to run into the label-
switching problem with mixture models, our MCMC chain does not yield such issues
because the cluster memberships do not change post burn-in. For our simulation
study with five total clusters, this point estimate gives three empty clusters, two
large clusters with 179 and 198 subjects that correspond to the two true clusters in
the simulated data, and all 123 subjects correctly identified as non-progressors.
The convergence for the MCMC chain was assessed using R package coda and
displayed no issues of non-convergence. The trace plots (Figure 4.1) and summary
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table (Table 4.1) of the change point parameters, τh and γh, and the cure status
regression parameter, βc, show good mixing of the chain and the estimates are close
to the truth.
Cluster 1 Cluster 2
True τh 3 5
τh Post. Mean (95% CI) 3.044(2.634,3.388) 5.081(4.682,5.533)
True γh 0.1 0.1
γh Post. Mean (95% CI) 0.103(0.1,0.106) 0.099(0.096,0.103)






































































































Figure 4.1: Post burn-in trace plots for change point and cure status parameters.
The red line represents the true value. The last index in βc refers to the dimension
number.
To evaluate the longitudinal model performance, we computed the predictive mean
and 95% credible intervals for selected subjects using the MCMC posterior samples.
The longitudinal measurements and true longitudinal mean across time is plotted in
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Figure 4.2 along with the predictive mean and 95% credible intervals for three ran-
domly selected subjects with different cluster membership and cure status, demon-
strating that our model is able to reliably recover the true longitudinal process with
change points.
Our model fitting results also allows us to carry out predictive inference for the
cure status and diagnosis times of current or future subjects. The details of predictive
posterior inference is provided in Section 4.6.1. We randomly select a progressor from
our dataset that is female with 20.5 years of education and had a censored diagnosis
event. We sample the predictive probability of being a progressor and plot the density
in Figure 4.3(a). The predictive density covers the true value probability (0.916) and
gives a predictive mean probability of 0.912. The density of the predictive diagnosis
event time conditional on the subject being a progressor is provided in Figure 4.3(b)
and covers the true unobserved diagnosis time of 78.9 years. Thus, we can construct
the predictive density of the diagnosis event time for this subject to be a mixture
distribution with probability 0.088 assigned to the point mass of Ui = ∞ and with
probability 0.912 assigned to the density in Figure 4.3(b).
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Post. Predictive E[Y] 95% CI



















































Post. Predictive E[Y] 95% CI
(a) Subject 1: Cluster 1, si = 1 (b) Subject 2: Cluster 2, si = 1













































Post. Predictive E[Y] 95% CI
(c) Subject 3: si = 0
Figure 4.2: These panels plot the longitudinal observations (dots) and true longi-
tudinal mean (black line) across time and the predictive mean (red line) and 95%
credible intervals (dashed red lines) for three randomly selected subjects, with differ-






























(a) Progressor Probability (b) Diagnosis event time
Figure 4.3: These panels plot the posterior predictive densities for the diagnosis time
and probability of being a progressor for a randomly selected subject. The red lines
represent the true unobserved diagnosis time and probability of being a progressor.
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4.4 Real Data Analysis
In this section, we analyze the data from the BIOCARD study for for I = 313 sub-
jects that longitudinally tracked biomarkers associated with the development of cog-
nitive impairment, particularly Alzheimer’s disease. Our analysis uses the biomarker
measurements for plasma levels of phosphorylated tau181 (ptau181) in the cere-
brospinal fluid (CSF) of subjects. All subjects in this study started with a normal
cognitive status and several baseline risk factors were initially collected when sub-
jects joined the study: years of education (Educ), sex (female=1), and the presence
of the ε4 allele in the Apolipoprotein E gene (APOE), defined as 1 indicating presence
of the allele, and 0 indicating no presence. Table 4.2 summarizes subjects’ baseline
characteristics.
Years of Education (years)








Table 4.2: Subject characteristics at baseline.
The subjects’ cognitive abilities are repeatedly diagnosed and the diagnosis event
of Alzheimer’s disease is defined in our context as an onset of mild cognitive impair-
ment (MCI) or dementia. Out of our 313 subjects, 101 have an observed diagnosis
time (67.7 % censoring rate) and the largest age at diagnosis was 97.4 years. The
Kaplan-Meier plot for the diagnosis times by subject age is provided in Figure 4.4
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and suggests that roughly 20% of subjects will not have a diagnosis for AD by age
97.





























Figure 4.4: Kaplan-Meier plot for the Alzheimer’s disease diagnosis event.
4.4.1 Results: model fitting and posterior infer-
ence
We applied the proposed Bayesian joint model to the BIOCARD data with Xi,j =
(1,Educ, Sex,APOE, ti,j), Zi,j = Xi,0 = (1,Educ, Sex,APOE). The hyperparameters
were set to the same as in the simulation study and we ran the same three-step
MCMC inference. In each step, we used a finite DPM with five total clusters and had
10,000 MCMC iterations, an initial burn-in of 5,000 iterations, and a thinning factor
of 10. The first step of assuming no cure to construct a pseudo prior for the diagnosis
event times, U , yielded a marginal posterior density with a mean of 84.2 years and a
standard deviation of 12.3 years.
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After constructing a pseudo prior for U , we fit our proposed model to the data
using another 10,000 MCMC iterations. Using these posterior samples, we sample
from the predictive posterior distributions of diagnosis event times and probability
of being a progressor for two randomly selected subjects and plot the densities in
Figure 4.5. Subject R1 is male with 16 years of education and positive APOE status
while subject R2 is female with 18 years of education and negative APOE status. As
a result of their varying baseline characteristics, these two subjects have significant
differences in the predictive densities for probability of being a progressor and subject
R1 has a predictive mean probability of 0.98 while subject R2 has a probability of
0.54. Subject R1’s predictive density for diagnosis time is a mixture distribution with
a 0.02 probability for Ui = ∞ (non-progressor) and a 0.98 probability assigned to
the predictive density in Figure 4.5(b), which has a mean of 80.3 years. In contrast,
Subject R2’s diagnosis time predictive density is a mixture distribution with a 0.46
probability of Ui = ∞ and a 0.54 probability to follow the density in Figure 4.5(d),
which has a mean of 82.6 years.
Parameter estimation under a mixture model such as the DPM for diagnosis event
times is complicated by the label switching problem, where the unidentifiability of
clusters makes it difficult to interpret parameter estimation results. To resolve this
issue, we construct point estimates of clustering based on the least-squares distances
from the posterior probabilities of subject pairs sharing the same cluster (Vannucci
et al., 2009). We then use these point estimates of clusters to fix the cluster member-
ship of each subject, and continue to run another 10,000 MCMC iterations. The con-
vergence for all three MCMC chains, each with 10,000 iterations, was assessed using
R package coda and showed no issues of non-convergence. Fixing the cluster member-
ship results in 75 subjects (24% of all subjects) being identified as non-progressors.
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(a) Subject R1- Progressor Probability (b) Subject R1- Diagnosis event time






























(c) Subject R2- Progressor Probability (d) Subject R2- Diagnosis event time
Figure 4.5: These panels plot the posterior predictive densities for the diagnosis
time and probability of being a progressor for two randomly selected subjects.
The remaining 238 progressors were clustered into five groups and baseline statistics
and change point estimation results are summarized in Table 4.3. Cluster 5 contains
most of the progressors and the slope change at the change point, γh, is close to zero
and its 95% credible interval covers zero. Thus, we believe these 153 subjects have no
change point. The other four clusters have varying change points between 3 and 13
years before the diagnosis time. Subjects in clusters 1 and 2 experienced a decrease
in the slope at the change point while clusters 3 and 4 had their slopes increase at
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the change point. Compared to the five progressor clusters, the non-progressors had
more education (mean of 17.35 years), a significantly higher percentage of females
(74.67%), and a significantly lower percentage of APOE (2.67%).
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
N 39 16 26 4 153
Mean Educ. 17.14 16.94 16.96 17 16.78
% Female 56.41 37.5 57.69 50 52.94
% APOE 51.28 68.75 46.15 50 39.87
τh Post. Mean 12.83 10.18 7.66 3.54 17.72
τh Post.95% CI (1.64,20.92) (6.75,14.94) (6.26,9.03) (0.57,7.66) (11.52,24.34)
γh Post. Mean -1.17 -2.12 3.4 2.66 0.01
γh Post.95% CI (-2.43,-0.65) (-2.47,-1.82) (2.97,3.81) (1.31,4) (-0.09,0.12)
Table 4.3: Summary of results with fixed clusters
We plot the longitudinal measurements of ptau181 grouped by cluster membership
in Figure 4.6, where the zero on the x-axis is the posterior mean of the change
point. The slopes of the longitudinal process significantly changes at the change point
for clusters 1-4 but remains stable in cluster 5. Figure 4.7 plots the longitudinal
measurements of the non-progressors and progressors. The non-progressors have a
significantly flatter slope and lower variance in the ptau181 longitudinal trajectories
compared to the progressors. These findings agree with studies in the literature that
identify high levels of ptau181 as a diagnostic tool for Alzheimer’s disease (Thijssen
et al., 2020).
Figure 4.8 plots the trace plots for the cure status coefficient, βc, which has a
posterior mean of (0.83,-0.28,-0.83,2.05). Years of education is negatively associated
with being a progressor for AD, which aligns with findings in Sharp and Gatz (2011)
that have shown that low education increases the risk of dementia. Furthermore, our
analysis finds that the presence of the APOE ε4 allele significantly increases the risk
of developing AD, agreeing with previous clinical studies that identify APOE ε4 as
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(a) Cluster 1 (b) Cluster 2






























(c) Cluster 3 (d) Cluster 4
















Figure 4.6: These panels plot the ptau181 biomarker for progressors grouped by clus-
ter membership. Zero on the x-axis is the posterior mean of the change point. Each
line represents the measurements for one subject and the red line segments are mea-
surements after the AD diagnosis, when the subject is experiencing MCI/dementia.
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(a) Non-Progressors (b) Progressors
Figure 4.7: These panels plot the ptau181 biomarker for each subject, grouped by
cure status. The zero on the x-axis is Ti.
the most prevalent genetic risk factor of AD (Safieh et al., 2019)






































































Figure 4.8: Post burn-in trace plots for cure status parameters, where the last index
in βc refers to the dimension number.
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4.5 Conclusion
In this chapter, we developed a semiparametric Bayesian framework that jointly
models longitudinal biomarker measurements, latent cure status, and diagnosis event
times. The model simultaneously identifies a change point in the longitudinal evolu-
tion of a disease that precedes diagnosis time, accounts for the possibility of individual
disease non-progression, and clusters subjects using longitudinal and diagnosis time
data. Through simulation studies, we demonstrated that our model is able to reliably
cluster subjects with similar longitudinal and diagnosis event time patterns, compute
the personalized probability of being a disease progressor, and recover the true under-
lying longitudinal and diagnosis event time processes. We applied our proposed model
to the BIOCARD dataset, yielding clinically relevant results and detecting longitu-
dinal change points in the ptau181 biomarker for select subjects occurring between 3
and 13 years before an official diagnosis for Alzheimer’s disease.
There are a number of possible extensions for our methods. Firstly, we consider
one longitudinal biomarker measurement in the longitudinal process, which can be
expanded to a multivariate analysis of multiple longitudinal biomarkers. Secondly,
we can allow for individual heterogeneity in the change point years before diagnosis
event, τh. In our current setup, this value is fixed and shared among all subjects in
the same cluster.
4.6 MCMC Details
For our finite DPM model, we work with mixtures of a large but finite number
(H) of clusters. We use ri = h to indicate that i-th subject is assigned to h-th




progressors and Bi(βc) for non-progressors. Then for progressors, Bi,h(βc,βuh, σ
2
uh) =
Φ(βTcXi,0)p(Ũi ≥ ti1 | si = 1, ri = h,βuh, σ2uh,Xi,0) + (1 − Φ(βTcXi,0)), where Ũi
represents the diagnosis time: either the observed diagnosis time, Ui (δi = 1), or the
imputed diagnosis time for subjects with a censored diagnosis time (δi = 0). For non-




h=1whp(Ũi ≥ ti1 | si = 1, ri = h,βuh, σ2uh,Xi,0) +
(1 − Φ(βTcXi,0)). Furthermore, let Yi = (Yi,1, . . . , Yi,Ji)T , ti = (ti,1, . . . , ti,Ji), Xi =
(Xi,1, . . . ,Xi,Ji), and Zi = (Zi,1, . . . ,Zi,Ji).
1. Update ri for i ∈ J0 := {i : si = 0} :
If si = 1 and δi = 0 :
p(ri = h | · · · ) =
whΦ(Ũi | βTuhXi,0, σ2uh)p(Yi | ri = h, · · · )Bi,h(βc,βuh, σ2uh)∑H
h=1whΦ(Ũi | βTuhXi,0, σ2uh)p(Yi | ri = h, · · · )Bi,h(βc,βuh, σ2uh)
where Φ refers to the normal distribution CDF.
If si = 1 and δi = 1 :
p(ri = h | · · · ) =
whp(Ũi | βTuhXi,0, σ2uh)p(Yi | ri = h, · · · )Bi,h(βc,βuh, σ2uh)∑H
h=1whp(Ũi | βTuhXi,0, σ2uh)p(Yi | ri = h, · · · )Bi,h(βc,βuh, σ2uh)
.
2. Update vh for h = 1, · · · , H − 1.









3. Update si for i ∈ J0 := {i : δi = 0}








h=1 whp(Yi | Ũi, si = 1, ri = h, · · · )p(Ũi | βuh, σ2uh,Xi,0),
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P0 = (1 − Φ(βTcXi,0))p(Yi | Ũi, si = 0, · · · )π(Ũi), and π(·) is pseudo prior for
non-progressors.
4. Update s∗i , (truncated normal),
p(s̃∗i | ri = h, · · · ) =

N (βTcXi,0, 1)I(0,∞) si = 1


















f(βc | · · · ) ∝ N (m̃c, Ṽc)
I∏
i=1
p(min(Ũi, Di) ≥ ti1 | βc, · · · )










We use the Metropolis Hastings algorithm with a proposal distribution ofN (m̃c, Ṽc).
The acceptance probability of the proposed β∗c is:

























6. Update Ũi, for i ∈ J0 := {i : δi = 0}
Given si = 0, we simulate Ũi from pseudo prior π(·). If si = 1, then we want to
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sample from:
p(Yi | Ũi, si = 1, · · · )p(Ũi | ri = h,βuh, σuh)I(Ũi>Ti)
∝ exp
(













, where µi,j = Yi,j − βT2hXi,j − bT2iZi. If we let Ki denote the number of visits
after Ti−γh, then we need to sample from a mixture of Ki+1 truncated normal
distributions. If we define ti,0 = 0 and ti,Ji+1 = ∞, the k-th truncated normal























The probability of sampling from each of the Ki + 1 truncated normal distribu-

























f(βuh | · · · ) ∝ N (m̃u, Ṽu)
∏
i:ri=h,si=1
p(min(Ũi, Di) ≥ ti1 | βuh, · · · )






We use the Metropolis Hastings algorithm with a proposal distribution ofN (m̃u, Ṽu).














8. Update σ2uh. The full conditional for σ
−2
uh is









(Ũi − βTuhXi,0)2 .
f(σ2uh | · · · ) ∝ Inv-Gamma(ã0, b̃0)
∏
i:ri=h,si=1







We use the Metropolis Hastings algorithm with a proposal distribution of




















9. Update β1h, β2h, and γh. The full conditional distributions are in standard
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form, given as
f(β1h | · · · ) ∝ N (m̃1, Ṽ1)
Ṽ1 =
(


















f(β2h | · · · ) ∝ N (m̃2, Ṽ2)
Ṽ2 =
(
















Xi(Yi − bT2iZi − γh(ti − Ũi − τh)+)
)























10. Update b1i for i ∈ J1 := {i : si = 0} and b2i for i ∈ J2 := {i : si = 1},




































Zi(Yi − βT2hXi − γh(ti − Ũi + τh)+)
)
.
11. Update Vb1 , and Vb2 ,
























12. Update σ1, and σ2,











(Yi − βT1hXi − bT1iZi)T (Yi − βT1hXi − bT1iZi)













where Mi,h = Yi − βT2hXi − bT1iZi − γh(ti − Ũi + τh)+
13. To update change point variable τh, there is no closed form formula, and we
can use Metropolis-Hastings algorithm to generate τ ∗h from Uniform(aτ , bτ ), and
accept it with probability





f(Yi | τ ∗h , · · · )∏
i:ri=h,si=1




The posterior predictive distribution for the diagnosis time of a progressor i with




































where ta0 represents the t-distribution with a0 degrees of freedom, the entire dataset
is denoted Dn = {Yi, ti,Xi,Zi,Xi,0, δi, Ui}ni=1, Ih denotes the number of subjects in
the h-th cluster, and Is denotes the total number of progressors.
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